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ABSTRACT
Acne is one of the most common skin disorders in the United States, occuring in over 5.1 million
Americans. Of those with acne, 53.8% are adults between the ages of 18 and 44 years old
(American Academy of Dermatology [AAD], 2017). Acne can lead to multiple issues such as
scarring, poor self-esteem, anxiety, and depression (Zaenglein et al., 2016). Acne can also
negatively impact quality of life (Cengiz & Gurel, 2020). The purpose of this evidence-based
project was to develop a cost-effective treatment algorithm for the management of acne vulgaris
in adult college students. A literature search determined the best and most cost-effective agents
to manage acne are benzoyl peroxide 2.5%, adapalene 0.1%, clindamycin phosphate 1%, and
doxycycline. These agents are used in varying combinations based on acne severity level,
which can range from clear, almost clear, mild, moderate, severe, and very severe. A treatment
algorithm was developed based on the literature recommendations and implemented by two
nurse practitioners at a university student health center located in Northwest Indiana. Two
groups of participants were included in this study, an intervention group that received treatment
and a comparison group that did not receive treatment. The primary outcome being measured
was participant quality of life measured by the Acne-Specific Quality of Life (Acne-QoL)
Questionnaire, which is separated into four specific domains. Participants completed this
questionnaire during baseline visits and again after 6 weeks of treatment. Data were analyzed
using paired-samples t tests for both the intervention and comparison groups, as well as a
mixed-design ANOVA between groups. For the intervention group there were statistically
significant increases in quality of life for the self-perception (t (9) = -3.171, p = .011), roleemotional (t (9) = -2.675, p = .025), and acne symptoms (t (9) = -3.48, p = .007) domains. No
statistically significant difference was found between mean baseline and 6-week scores for the
comparison group. There was also no statistically significant difference between the two groups.
The results from this project can be implemented into practice to provide consistent
management of acne vulgaris and to improve patient quality of life.

ix

ACNE VULGARIS TREATMENT ALGORITHM

1

CHAPTER 1
INTRODUCTION
Background
Acne is one of the most common skin disorders in the United States, primarily affecting
adolescents and young adults (AAD, 2017). Acne is typically first seen in adolescents during
puberty; however, it can continue into adulthood (Pandis, 2020; Zaenglein et al., 2016). In 2013
alone, over 5.1 million Americans were seen in the health care setting for treatment of acne.
Among those individuals, 53.8% were between the ages of 18 and 44 years old (AAD, 2017).
Acne poses a significant cost burden to patients as it was reported in 2013 that acne accounted
for $846 million dollars in medical costs. Lost productivity for patients and caregivers was also
noted to be $398 million dollars (AAD, 2017). Not only does acne have a high-cost burden on
patients, but it can also cause other physical or psychological issues such as scarring, poor selfesteem, anxiety, and depression (Zaenglein et al., 2016). These factors can lead to an overall
negative impact on an individual’s quality of life (Cengiz & Gurel, 2020).
There are different variants of acne including acne vulgaris, acne mechanica, acne
fulminans, and chloracne, among others (Wolff et al., 2017). Acne vulgaris, or common acne, is
the most prevalent type, occuring in 99% of acne cases (Ramli et al., 2012). The
pathophysiology of acne vulgaris involves four key processes including inflammation, abnormal
desquamation of keratinocytes, increased or altered sebum production, and colonization of
Propionibacterium acnes (Pandis, 2020). Puberty triggers increased hormone stimulation which
then increases sebum production in pilosebaceous follicles. The abnormal desquamation of
keratinocytes causes the pilosebaceous follicles to become clogged, leading to the formation of
primary lesions, also known as comedones. There are two types of comedones, open and
closed. Open comedones are also known as blackheads and closed comedones as whiteheads.
Open comedones are the result of an obstruction at the follicular head and closed comedones
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occur due to swelling of the follicular duct. Closed comedones are the precursor to inflammatory
lesions, such as papules and pustules, which occur due to inflammatory materials that surround
the comedone (Pandis, 2020). Nodules and cysts may also develop with acne vulgaris (Wolff et
al., 2017).
Data from the Literature Supporting Need for the Project
As previously stated, acne vulgaris is one of the most common skin disorders in the
United States (AAD, 2017). Acne vulgaris primarily affects adolescents and young adults, and it
is estimated that 85% of individuals between the ages of 12 and 24 years old have at least a
mild form of acne (Bhate & Williams, 2013). This specific age population comprises most
college students, who are young adults. Acne can have many detrimental effects for these
young adults, including scarring, poor self-esteem, anxiety, and depression (Zaenglein et al.,
2016). The negative impacts acne can have on mental health have also been outlined by
Singam et al. (2019), in which an analysis of the 2002-2012 United States National Inpatient
Sample was conducted to determine associations between acne vulgaris and comorbid mental
health disorders in hospitalized pediatric and adult patients. In this study, the authors
determined acne vulgaris can be associated with numerous comorbid mental health disorders
including anxiety, depression, adjustment disorders, schizophrenia, suicidal risk, personality
disorders, attention deficit disorder/attention deficit hyperactivity disorder and other conduct
disorders, alcohol-related disorders, childhood and adolescent psychiatric illnesses,
development disorders, impulse control disorders, cognitive disorders, a history of mental health
disorders, and substance use disorders (Singam et al., 2019). Individuals suffering from acne
vulgaris can also have trouble with emotion regulation, which can negatively impact quality of
life (Cengiz & Gurel, 2020).
The negative impacts of mental health disorders and difficulty with emotion regulation
caused by acne vulgaris can make a young adult’s life in college more challenging. These
factors may also lead to lower academic performances as well (Girman et al., 1996). College
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itself can be a stressful time for most young adults in general, and this increased stress can also
be a major trigger for acne vulgaris (Pandis, 2020). Not only does stress contribute to acne
exacerbations, but poor diet choices may also lead to an increase in acne. Specifically, there
have been associations between diets with a high glycemic load and increased acne
exacerbations. It is thought that dairy products may also play a role in acne exacerbations as
well (Pandis, 2020).
Data from the Clinical Agency Supporting Need for the Project
The clinical site for this EBP project was a university student health center located in
Northwest Indiana. The director of the student health center, who also works as a family nurse
practitioner (FNP) at the clinic, determined there was a need for a treatment algorithm to
adequately treat patients presenting to the clinic with acne. A chart review also determined there
were inconsistent prescribing trends for the treatment of acne over a period of 3 years. Acne
severity levels were also not consistently assigned to patients, in which only 22% of patients
seen in the clinic for acne received a severity level of either mild or moderate. These severity
levels were based on provider judgement, as there was no standardized acne grading scale
used within the student health center during this time period.
Purpose of the Evidence-Based Practice Project
The purpose of this EBP project is to improve patient quality of life using a cost-effective
treatment algorithm for the management of acne vulgaris in adult college students. The goal of
cost-effective treatment is to reduce any financial barriers patients may have when obtaining
treatment for acne.
PICOT Question
The PICOT question developed for this project was: in adult college students diagnosed
with acne vulgaris at the university’s student health center (P), how does a cost-effective acne
treatment algorithm (I) compared to current practice without an algorithm (C) impact participant
quality of life measured by the Acne-QoL questionnaire (O) over a 6-week period (T)?
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Significance of the EBP Project
Young adults have a high prevalence of acne vulgaris, which can cause significant
issues related to mental health (Singam et al., 2019), difficulty with emotion regulation (Cengiz &
Gurel, 2020), as well as scarring and poor self-esteem (Zaenglein et al., 2016). During college,
there are also many changes that are occurring in a young adult’s life that can contribute to
acne vulgaris, including increased levels of stress and unhealthy eating habits. Treatment for
acne can also be costly, and many college students are typically on a budget. Overall, the
development of a cost-effective treatment algorithm can help to alleviate the financial burden
experienced by students seeking treatment for acne vulgaris, as well as to ensure treatment is
adequately managed based on acne severity level. The treatment algorithm can also serve as a
standardized treatment modality to ensure consistency and easy to follow guidance for
healthcare providers.
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CHAPTER 2
EBP MODEL AND REVIEW OF LITERATURE
Evidence-based Practice Model
Overview of EBP Model
After careful review of the various EBP models, the revised Iowa Model was selected as
a guide for the development, implementation, and sustainability of this EBP project. The model
was originally developed at the University of Iowa Hospitals and Clinics (UIHC) by a group of
nurses to develop a process for EBP. The model was also recently revised and validated in
2017 in an attempt to stay current with changes in the healthcare field (Iowa Model Collective,
2017). The Iowa Model is based on Martha Rogers’ Diffusion of Innovations theory and was
developed based on the scientific problem-solving process for use among interdisciplinary
healthcare providers (Melynk & Fineout-Overholt, 2019). This model features a series of seven
steps incorporated with feedback loops, as well as three decision points in between steps to
assist in the guidance of the EBP process.
Step one of the Iowa Model involves identifying triggering issues or opportunities. The
trigger or opportunity can arise from clinical- or patient-identified issues; organizational, state, or
national initiatives; data or new evidence; accrediting agency requirements or regulations; or
philosophy of care (Melynk & Fineout-Overholt, 2019). This then leads into the next step of
stating the question or purpose. This step involves the development of a PICOT question, and
ultimately, this step helps to reinforce the focus of the EBP process. Following step two, there is
a decision point in which it must be determined if the selected topic is a priority. If the answer is
no, the first feedback loop is encountered, and another issue or opportunity should be explored
that is a higher priority. If answered yes, the EBP process is continued into step three: form a
team. The team is composed of key stakeholders and organizational leaders to lead the process
of practice change (Melynk & Fineout-Overholt, 2019). Step four involves the process of
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assembling, appraising, and synthesizing the body of evidence through a systematic search.
Following this step, another decision point must be made to determine if there is sufficient
evidence. If there is not, a feedback loop is followed in which research must be conducted and
then reassembled. If there is sufficient evidence, the process continues into step five. This step
includes designing and piloting the practice change which involves engaging patients and
verifying preferences; considering resources, constraints, and approvals; developing localized
protocols; creating an evaluation plan; collecting baseline data; developing an implementation
plan; preparing clinicians and materials; promoting adoption; and collecting and reporting postpilot data (Melynk & Fineout-Overholt, 2019). After completing these various tasks within step
five, another decision point is encountered to determine if the change is appropriate for adoption
in practice. If the change is not appropriate, another feedback loop is followed to consider
alternatives and to then redesign the change. If the change is appropriate, the EBP process
continues to step six: identify and sustain the practice change. For this step, tasks include
identifying and engaging key personnel, hardwiring the change into the system, monitoring key
indicators through quality improvement, and reinforcing as needed (Melynk & Fineout-Overholt,
2019). Finally, the process ends at step seven which includes disseminating the results to
promote EBP among other clinicians and organizations.
Application of EBP Model to DNP Project
The steps of the Iowa Model were followed throughout the duration of this project to
serve as a guide for the EBP process. The triggering issue was identified by the director of the
student health center after determining there was inconsistency of treatment for acne vulgaris
among health care providers. Thus, it was determined that a treatment algorithm for acne
vulgaris would benefit the health care providers and their patients. Key stakeholders were
identified to form the team and included patients, staff nurses, health care providers, and the
health center director. After this step, a thorough literature search was conducted to determine
the best evidence available for managing acne vulgaris. Evidence was appraised to determine
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the level and quality ratings and was then synthesized to reflect best practice recommendations.
Based on these synthesized recommendations, a treatment algorithm was developed with a
plan to begin implementing said algorithm at the student health center among the health care
providers. This plan was communicated to the key stakeholders for implementation. Primary
outcomes were also identified for the evaluation phase of this project. Based on the evaluation,
sustainability of the practice change was discussed with stakeholders to continue utilizing the
treatment algorithm in practice.
Strengths and Limitations of EBP Model for DNP Project
One strength of the Iowa Model includes the practicality and ease of use of the model.
The seven steps are clearly identified and the decision points between steps two, four, and five
allow the user to determine if the project is progressing in the right direction. The various
feedback loops also help the user return to previous steps to revise a project as needed. This
simplicity makes using the revised Iowa Model an easy process among both novice and expert
clinicians. Another identified strength of this model involves the recent revisions to stay current
with the ever-changing healthcare field. Revisions were recently made to address “an explosion
of synthesized evidence, national and international initiatives promoting adoption of EBP,
enhanced interprofessional collaboration, widespread use of electronic data, emergence of
implementation science, pay for performance, and enhanced patient engagement” (Iowa Model
Collective, 2017, p. 175).
One limitation of the Iowa Model would be the time required to complete the various
steps. There are multiple tasks for each step, especially for steps four, five, and six. This may
pose a problem when clinicians and key stakeholders are limited on time for the completion of a
project. However, time can be saved throughout the project as mentioned before with the use of
the decision points and feedback loops that are presented throughout the model. These
decision points and feedback loops are beneficial in that time will not be wasted if the project
does not meet the necessary criteria to continue. Overall, the strengths greatly outweigh the one
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limitation of this model and this model provided an excellent framework for the duration of this
project.
Literature Search
Sources Examined for Relevant Evidence
An extensive literature search was conducted to identify best practice interventions for
the management of acne vulgaris. Multiple databases were systematically searched including
Cochrane Library, Joanna Briggs Institute (JBI), Turning Research into Practice (TRIP) Medical
Database, MEDLINE via EBSCO, and Cumulative Index to Nursing and Allied Health Literature
(CINAHL). Cochrane Library and JBI were selected based on their collection of high levels of
evidence. TRIP Medical Database was utilized as it includes various clinical practice guidelines.
CINAHL and MEDLINE were also selected based on their large collections of scholarly
evidence. Citation chasing from relevant sources was also completed to ensure a thorough
literature search was conducted. Keywords utilized for the final literature search included acne,
“acne vulgaris”, “comedonal acne”, Medical Subject Heading (MeSH) term “Acne Vulgaris”,
MeSH term “Dermatologic Agents”, CINAHL subject heading “Acne Vulgaris”, and CINAHL
subject heading “Dermatologic Agents”, all in varying combinations based on the selected
database.
Inclusion criteria consisted of a date range from 2015 to 2020, English language,
scholarly/peer-reviewed sources, adolescent age group (13-18 years), and all adults age group
(19 years and older). Within the TRIP Medical Database, the inclusion criteria “guidelines” was
also utilized. Exclusion criteria consisted of adolescents younger than 18 years old and
evidence based on other variants of acne such as acne fulminans, acne varioliformis, acne
aestivalis, and acne tropica. Studies involving the use of isotretinoin were also excluded after
completing a cost analysis of various acne treatment regimens as isotretinoin is a more
expensive medication. It was determined through the literature search that the vast majority of
evidence suggests treatment should involve the use of topical and systemic medications. Thus,
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studies involving diet, complementary and alternative medicine (CAM), light/laser therapy, and
herbal remedies were excluded. Evidence involving the use of oral contraceptives were also
excluded based on their exclusive use within female patient populations.
The initial literature search began in the Cochrane Library database. The first search
utilized within this database involved the keywords (acne OR “acne vulgaris” OR “comedonal
acne”) AND (treat* OR interven* OR manag*) with limiters of the past five years. This search
yielded 93 results, many of which were irrelevant to the topic. At the advice of the Valparaiso
University library liaison, Kimberly Whalen, the keywords treat*, interven*, and manag* were
omitted from the search based on the yielded results. Acne was also removed as a keyword
based on advice from the library liaison as the use of this keyword was yielding evidence where
acne could have been simply mentioned within a piece of evidence, without regard to the
selected topic. With the removal of these keywords, a final search was conducted involving the
keywords “acne vulgaris” OR “comedonal acne.” This final search yielded 14 results, of which
five were reviewed and one accepted for use within this project.
The next database searched was JBI. The search was kept simple within this database
based on recommendations made by the library liaison. Thus, this search involved the use of
the single keyword acne. A date limit of the last five years was also utilized within this database.
This search yielded 21 results. Many results were deemed irrelevant to the topic, thus only one
piece of evidence was reviewed. This piece of evidence was later excluded from the project
based on the exclusion criteria as it involved the treatment modality of oral contraceptives to
manage acne vulgaris.
The TRIP medical database was utilized next. Keywords included “acne vulgaris” OR
“comedonal acne.” The limiters of last five years and USA guidelines were used as well, which
yielded 39 results. After careful consideration, a decision was made to remove USA guidelines
and to search guidelines from all countries within this database. USA guidelines seemed too
restrictive as guidelines from other countries can provide valuable information for use here in
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the USA. After modifying the search, a total of 118 sources were found. Three of those sources
were selected for use in this project.
To continue the literature search, MEDLINE via EBSCO was searched next. The initial
search within this database was too broad and resulted in 1,525 sources. Thus, the addition of
MeSH headings was utilized to narrow the search. The next search involved the keywords
(MeSH heading “Acne Vulgaris” OR “comedonal acne”) AND (interven* OR treat* OR manag*)
with the limiters English language, last five years, and scholarly/peer reviewed. This only
brought the number of sources down to 1,058. Based on the previous advice of the library
liaison, the keywords interven*, treat*, and manag* were eliminated. However, a new keyword
was needed to narrow the results further, as the search remained too broad. Thus, the MeSH
heading “Dermatologic Agents” was utilized as this heading was deemed relevant to the search
topic. The final search for this database involved the keywords MeSH heading (MH “Acne
Vulgaris” OR “comedonal acne”) AND MeSH heading (MH “Dermatologic Agents”). Further
limiters of adolescent (13-18 years) and all adult (19+ years) were also applied. This final
search yielded 212 results, of which two were selected for use in this project.
The final database searched was CINAHL. Based on the search from MEDLINE via
EBSCO, the same keywords and limiters were utilized within this database as well. The MeSH
headings used in MEDLINE via EBSCO were switched to CINAHL subject headings for this
selected database, as these headings were the same in CINAHL. This search resulted in 34
results, of which seven were duplicates from MEDLINE via EBSCO. A total of nine sources
were reviewed, however, none were selected for use in this project based on the inclusion and
exclusion criteria.
Citation chasing was also utilized during the literature search. A total of 14 sources were
identified from previously reviewed sources, and two were selected for use. One clinical practice
guideline was selected from a Cochrane Library systematic review. The other selected piece of
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evidence was a descriptive study referenced in an article previously reviewed that was originally
found in MEDLINE via EBSCO.
In total, this systematic literature search yielded 413 pieces of evidence. Numerous
pieces of evidence were eliminated based on simple review of titles and abstracts. Articles were
also removed if they were duplicates previously found within other databases. A total of 65
pieces of evidence were reviewed, and the final decision to include eight pieces of evidence
was made based on this review. Data from the literature search is represented in Table 2.1. The
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) process is also
shown in Figure 2.1.
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Table 2.1
Evidence Search Table

Database

Yielded

Duplicates

Reviewed

Accepted

Cochrane

14

0

5

1

JBI

21

0

1

0

TRIP

118

0

4

3

MEDLINE

212

1

32

2

CINAHL

34

7

9

0

Citation Chase

14

0

14

2

Total

413

8

65

8

Note. Databases are listed in order of searches performed.
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Levels of Evidence
The Melynk and Fineout-Overholt’s (2019) Hierarchy of Evidence was used for leveling
the evidence for this project. This hierarchy consists of a seven-level ranking system ranging
from Level I to Level VII. These levels are depicted as a pyramid, with the Level I evidence at
the top representing high-level evidence and Level VII evidence at the bottom of the pyramid
representing lower-level evidence. Evidence becomes more generalizable to patient populations
and has a lower risk of bias as each level of the pyramid grows from the bottom up. This
criterion allows for a degree of confidence that interventions defined within the evidence will
perform as they are intended to produce desired health outcomes (Melynk & Fineout-Overholt,
2019). The Level I evidence includes systematic reviews, meta-analyses, and clinical practice
guidelines based on Randomized Controlled Trials (RCTs). Level II evidence consists of single
RCTs, while Level III evidence consists of nonrandomized controlled studies. Continuing
through the pyramid, Level IV evidence is obtained from controlled cohort studies and Level V
evidence is obtained from uncontrolled cohort studies. Level VI evidence consists of case
studies, case series, qualitative studies, descriptive studies, EBP implementation, and Quality
Improvement (QI) projects. Finally, Level VII evidence is defined as evidence based on expert
opinion. In total, eight pieces of evidence were selected for use in this project, including one
systematic review (Level I), one meta-analysis (Level I), four clinical practice guidelines (Level
I), and two descriptive studies (Level VI). Levels of evidence are summarized in Table 2.2.
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Table 2.2
Levels of Evidence

Level

Included

Quality

Design

I

6

High (5)
Good (1)

Systematic Review (1)
Meta-Analysis (1)
Clinical Guideline (4)

VI

2

High (1)
Good (1)

Descriptive Study (2)
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Appraisal of Relevant Evidence
Appraisal of the selected evidence was completed using the Johns Hopkins Research
and Non-Research Evidence Appraisal Tools. The Johns Hopkins Research Appraisal Tool is
used to appraise the quality of quantitative and qualitative research studies, mixed-method
studies, systematic reviews with or without meta-analyses, and meta-syntheses. Thus, this tool
was used to appraise the one systematic review, one meta-analysis, and two descriptive
studies. The remaining evidence was appraised using the Johns Hopkins Non-Research
Appraisal Tool. This tool is used to evaluate evidence such as clinical practice guidelines,
consensus or position statements, literature reviews, integrative reviews, expert opinion, QI
projects, financial or program evaluations, case reports, community standards, clinician
experience, and consumer preference (Dang & Dearholt, 2017).
The Johns Hopkins Research and Non-Research Appraisal Tools are completed by
answering a series of questions to determine quality of evidence. These questions follow an
algorithm that determines whether evidence is ranked as high, good, or low quality. Using the
Research Appraisal Tool, quantitative evidence is ranked as high quality if the evidence meets
the following criteria: “consistent, generalizable results; sufficient sample size for the study
design; adequate control; definitive conclusions; consistent recommendations based on
comprehensive literature review that includes thorough reference to scientific evidence” (Dang &
Dearholt, 2017, p. 286). Evidence is ranked as good quality if the following criteria are met:
“reasonably consistent results; sufficient sample size for the study design; some control, and
fairly definitive conclusions; reasonably consistent recommendations based on fairly
comprehensive literature review that includes some reference to scientific evidence” (Dang &
Dearholt, 2017, p. 286). Finally, evidence is ranked as low quality with the following criteria:
“little evidence with inconsistent results; insufficient sample size for the study design;
conclusions cannot be drawn” (Dang & Dearholt, 2017, p. 286). This particular tool was used to
evaluate one systematic review, one meta-analysis, and two descriptive studies.
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The Johns Hopkins Non-Research Appraisal Tool was used to appraise the remainder of
the evidence, all of which were clinical practice guidelines. This type of evidence is ranked as
high quality when the following criteria are met: “material officially sponsored by a professional,
public, or private organization or a government agency; documentation of a systematic literature
search strategy; consistent results with sufficient numbers of well-designed studies; criteriabased evaluation of overall scientific strength and quality of included studies and definitive
conclusions; national expertise clearly evident; developed or revised within the past five years”
(Dang & Dearholt, 2017, p. 295). For evidence to qualify as good quality, the clinical practice
guideline needs to met the following criteria: “material officially sponsored by a professional,
public, or private organization or a government agency; reasonably thorough and appropriate
systematic literature search strategy; reasonably consistent results, sufficient numbers of welldesigned studies; evaluation of strengths and limitations of included studies with fairly definitive
conclusions; national expertise clearly evident; developed or revised within the past five years”
(Dang & Dearholt, 2017, p. 295). Finally, evidence is ranked as low quality or major flaw for the
following criteria: “material not sponsored by an official organization or agency; undefined,
poorly defined, or limited literature search strategy; no evaluation of strengths and limitations of
included studies; insufficient evidence with inconsistent results; conclusions cannot be drawn;
not revised within the past five years” (Dang & Dearholt, 2017, p. 295). After utilizing the
appraisal tools for all eight pieces of selected evidence, six pieces of evidence were deemed as
high quality and two as good quality. Appendix A provides a table with a summary of all
evidence and the corresponding appraisal.
Level I Evidence
Asai et al. (2015). This clinical practice guideline focused on adapting and updating
clinical recommendations from a previous guideline published by the European Dermatology
Forum (EDF), which was also used within this project (Nast et al., 2016). Overall,
recommendations were made to evaluate and treat acne vulgaris in both pediatric and adult
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patients based on their acne severity level, which ranged from comedonal, mild papulopustular,
moderate papulopustular, and severe papulopustular/nodular acne. The Canadian Skin Patient
Alliance has officially endorsed this guideline and it is also recognized by the Canadian
Dermatology Association and Acne and Rosacea Society of Canada. A thorough literature
search was conducted based on the methods used in the EDF guideline, which will be further
discussed for Nast et al. (2016). This search was updated from March 2010 to July 2015. The
inclusion criteria for evidence included human/clinical studies, systematic reviews, metaanalyses, RCTs, and controlled prospective studies. Recommendations for evaluating acne
involved determining the type, extent, and distribution of acne. This should be completed by
using a scale of clear, almost clear, mild, moderate, and severe/extreme. This scale can help to
determine changes over time after treatment has been initiated. Assessing patients’ quality of
life through direct inquiry or with instruments such as the Cardiff Acne Disability Index (CADI)
was also deemed to be helpful. Asai and colleagues (2015) provided a multitude of treatment
recommendations for the varying grades of acne. Such treatment recommendations from this
clinical practice guideline are summarized in the results and findings section of Appendix A.
Overall, this clinical practice guideline meets the criteria for high quality on the Johns
Hopkins Non-Research Appraisal Tool. While the authors did not specify how many or what
types of evidence they selected after the thorough literature search was completed, they did
provide adequate inclusion criteria that suggests only high-level evidence was utilized to
develop this guideline. The endorsement and recognition by various professional organizations
in Canada also suggest this guideline is of merit and value. Recommendations were clearly
stated; based on the supporting evidence identified during the literature search; and were
assigned strengths of recommendations including high, medium, low, negative, and open
strength. Recommendations included in the evidence for this project were those consisting of
high and medium categories. Those meeting the low, negative, and open strength categories
were excluded from the evidence.
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Friedman et al. (2016). The purpose of this meta-analysis was to discuss the
effectiveness of combination adapalene 0.1%/benzoyl peroxide 2.5% (A-BP) gel used for the
treatment of acne. Overall, data was reviewed from 14 clinical studies with a total of 2,358
subjects that were treated with A-BP. Outcomes measured within this piece of evidence
included lesion count, IGA, and tolerability of medication. The lesion counts were assessed at
baseline and during each subsequent visit. Post-baseline lesion count was subtracted from the
baseline lesion count to determine clinical improvement. Tolerability was assessed using a 4point scale ranging from none to severe to evaluate dryness, erythema, scaling, and stinging or
burning. These outcomes were measured over a period of 4 weeks. When compared to
baseline data, total lesion counts decreased 40.8% after four weeks. It was also noted that
inflammatory and noninflammatory lesions decreased 46.2% and 37.5%, respectively, from
baseline to week 4. Tolerability was ranked as none or mild for most subjects. Results from the
four categories of tolerability included 34.2% of subjects rating dryness as none and 49.0% as
mild; 34.2% rating erythema as none and 44.4% as mild; 43.3% rating scaling as none and
42.8% as mild; and 38.2% rating stinging or burning as none and 38.6% as mild. Ultimately, it
was determined that A-BP is well-tolerated, with minimal irritation, among subjects. These
results also suggest that A-BP can be used as a quick and effective treatment for various
severity levels of acne, in which improvement can be seen within as little as four weeks.
This meta-analysis was rated as good quality based on the critical appraisal. Results are
consistent and were obtained from a large sample of subjects. The authors conclusions are
clear and based on the review of 14 clinical studies. However, this meta-analysis lacks a
description of the literature search used to obtain the included studies, thus resulting in a quality
rating of good. The included sources are high levels of evidence, so this provides reassurance
that results are consistent and generalizable.
Le Cleach et al. (2017). The purpose of this clinical practice guideline was to provide
updates to the 2007 guideline for acne developed by the French Society of Dermatology. These
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updates were focused on addressing the use of antibiotics, isotretinoin, and hormonal therapy
for the treatment of acne vulgaris. In addition to these updates, a treatment algorithm for acne in
both adults and adolescents was updated and presented within this guideline. A thorough
literature search was conducted to find evidence published between the years 2007 and 2014.
This initial search was then updated to include references up to July of 2016. In total, 128
pieces of evidence were selected for inclusion within this guideline. The inclusion criteria for
sources of evidence consisted of systematic reviews, RCTs, and observational studies.
Treatment recommendations from this clinical practice guideline are summarized in the results
and findings section of Appendix A.
Overall, this clinical practice guideline was rated as high quality. It was not only
developed by the French Society of Dermatology but was also supported by the French National
Authority for Health. Documentation of a systematic literature search was included, and
although the number and type of evidence is not explicitly noted within this guideline, the
inclusion criteria suggest that high level evidence was selected for use. Clear and consistent
recommendations are made based on the selected evidence.
Nast et al. (2016). This was another clinical practice guideline with recommendations for
the treatment of acne vulgaris. These guidelines were developed by the EDF with a focus to
improve the care of acne patients, reduce serious conditions and scarring caused by acne,
promote treatment adherence, and reduce antibiotic resistance. This particular guideline is
categorized as a S3 guideline, meaning this is both an evidence- and consensus-based medical
guideline (Charite, 2020). A systematic literature search was conducted from 2010 to 2015.
Inclusion criteria for evidence consisted of RCTs that evaluated various acne treatments.
Overall, 154 studies were selected for inclusion within this guideline. Recommendations were
provided for both the evaluation and treatment of acne vulgaris. Ultimately it was determined
there is no recommended global system for measuring acne severity. Classification of acne for
the purposes of this guideline included comedonal acne, mild-moderate papulopustular acne,
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severe papulopustular acne/moderate nodular acne, and severe nodular acne/conglobate acne.
The subjective grading of acne severity, in addition to lesion counts, is considered practical for
clinical practice. Also, quality of life measures are recommended for acne management. Again,
no specific scale or questionnaire for evaluating quality of life has been identified. Treatment
recommendations from this clinical practice guideline are summarized in the results and findings
section of Appendix A.
This clinical practice guideline was rated as high quality after completing a critical
appraisal using the Johns Hopkins Non-Research Appraisal Tool. A high-quality rating was
assigned as the guideline was developed by the EDF; a professional organization founded by
European dermatologists with backgrounds in academia (EDF, 2020). A systematic literature
search was also conducted involving RCTs, and a sufficient number of studies were selected to
be included within this guideline. The recommendations outlined in this guideline were also
clearly and consistently stated.
Yang et al. (2020). This systematic review aimed to address the effectiveness of using
benzoyl peroxide (BP) for the treatment of acne. A thorough literature search was conducted in
multiple databases until February 2019. In total, 120 RCTs with 29,592 subjects were included
within this review. Subjects within the selected RCTs had either mild, moderate, or severe acne.
The two primary outcomes measured were participant self-assessment of acne improvement
using a Likert or Likert-type scale and withdrawal due to adverse events. Secondary outcomes
included investigator-assessed changes in lesion counts, percentage of participants considered
clear or almost clear on the IGA scale, changes in quality of life, reduction of C. acnes strains,
and percentage of participants experiencing adverse events. Comparisons were made between
BP and 47 other acne treatments, with five main comparisons consisting of placebo/no
treatment, adapalene, clindamycin, erythromycin, and salicylic acid.
The first comparison was BP and placebo/no treatment where participant selfassessment of improvement was slightly better with the BP group (RR = 1.27). However,
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participants were more than twice as likely to withdraw from BP treatment due to adverse
effects (RR = 2.13). Next, comparisons were made between BP and adapalene. There was no
difference for participant self-assessment of treatment improvement (RR = 0.99), however,
participants were again more likely to withdraw from BP treatment due to adverse effects (RR =
1.85). When comparing BP to clindamycin, participant self-assessment was slightly better within
the BP group (RR = 0.95), but once again participants were almost twice as likely to withdraw
due to adverse events (RR = 1.93). For the BP and erythromycin comparisons, there was no
data available for participant self-assessment of improvement. Also, there was no difference
between withdrawal rate between the two groups (RR = 1.0). Finally, there was no data
available for either primary outcomes for BP or salicylic acid comparison groups. These results
suggest that when compared to placebo or no treatment, BP may provide better outcomes
regarding patient self-assessment of improvement. While there was a high rate of withdrawal
due to adverse events caused by BP within the various comparison groups, these adverse
events were mostly related to tolerability issues involving irritation, erythema, pruritis, or skin
burning. These adverse events were mild to moderate in most cases as well. Even with this in
consideration, the results from this study indicate that BP may be an effective treatment option
for acne vulgaris.
Based on a careful and critical appraisal, this piece of evidence was rated as high quality
using the Johns Hopkins Research Appraisal Tool. This high-quality rating was assigned based
on the thorough literature search that was conducted and documented within the last five years.
This literature search also resulted in a sufficient number of RCTs that were included to
ultimately develop this systematic review. Also, recommendations from this systematic review
are clearly and consistently stated.
Zaenglein et al. (2016). The purpose of this clinical practice guideline was to provide
updated recommendations on the management of acne vulgaris in adolescent and adult
patients. This update served to replace an older version of this guideline published in 2007. This
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guideline was developed in accordance and approved by the AAD. A thorough literature search
was conducted between May 2006 and September 2014. Overall, no universal acne grading
system is recommended for determining acne severity level. Although a specific grading system
was not identified, it is recommended that a grading system be selected by clinicians and be
consistently used to determine acne severity and response to treatment. Treatment
recommendations from this clinical practice guideline are summarized in the results and findings
section of Appendix A.
After careful appraisal, this clinical practice guideline was deemed good quality. This
piece of evidence meets the criteria of being sponsored by the AAD, conducting a thorough
literature search, and having clear and consistent recommendations. However, there is no
mention of how many and what type of evidence were ultimately selected for inclusion, resulting
in a lower quality level. Normally, this would be rated as low quality based on the failure to meet
these criteria, however, there was mention that 242 pieces of evidence were retained for a final
review after sorting through evidence. These sources were selected based on relevancy, as well
as the highest level of available evidence. This suggests that high levels of evidence were
ultimately utilized to make the recommendations within this guideline, providing reassurance
that this is good quality evidence.
Level VI Evidence
Gollnick, Friedrich, et al. (2015). This descriptive study aimed to determine the
effectiveness and safety of combination adapalene 0.1%/benzoyl peroxide 2.5% for long-term
management of moderate to severe acne vulgaris. This study took place within 178 centers in
Germany. Observations were made among 5,141 patients with a diagnosis of moderate or
severe acne vulgaris for safety assessments, and of those patients, 5,131 were selected for
efficacy assessments. Diagnosis was based on grades 4-12 of the Leeds Revised Acne
Grading Scale. Observations took place for a period of nine months. Patients were also selected
based on indications for either A-BP alone or in combination with other acne treatment
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regimens. Both safety and tolerability were assessed using a 4-step scale, including none, mild,
moderate, or severe, to evaluate local skin irritation. Skin irritation was defined as having issues
such as erythema, dryness, desquamation, burning or stinging, and pruritis. Assessments were
made at each follow up visit. Patient-rated tolerability of treatment was also assessed at each
follow up visit using a 4-step scale including measures of very good, good, satisfactory, and
poor. Adverse drug reactions were assessed during each visit as well. Efficacy was measuring
using the Leeds Revised Acne Grading System, as well as physician assessment rated as very
good, good, satisfactory, or poor. These assessments were made to note any changes in the
severity of acne at each visit.
Overall, acne severity decreased from 5.6 ± 1.5 at baseline to 3.3 ± 1.9 at three months
after initiation of treatment and down to 1.9 ± 1.9 at nine months based on the Leeds Revised
Acne Grading System. After treatment, 420 patients (8.2%) experienced completely clear,
meaning no visible lesions, at three months and 1,326 patients (25.8%) at nine months.
Treatment was similar between patients who received A-BP alone and those who were
receiving A-BP in combination with a systemic antibiotic. Physician assessment of treatment
efficacy was rated as good or very good for 83.1% of patients. Patient assessment of tolerability
was rated as good or very good for 90.2% of patients. Overall, 49.5% of patients experienced
some type of skin irritation. Of the 49.5% of patients, 30.7% experienced dryness, 24.3%
experienced erythema, and 22.4% experienced desquamation. Adverse drug reactions occurred
in only 40 patients (0.008%).
Using the Johns Hopkins Research Appraisal Tool, this study was deemed high quality
based on the consistent and generalizable results reported in this study. An adequate sample
size of 5,131 patients were also included within this study to support the high quality rating.
Definitive conclusions and recommendations are drawn from the study, suggesting the safe and
efficacious use of A-BP for the treatment of moderate to severe acne vulgaris.
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Gollnick, Funke, et al. (2015). The purpose of this descriptive study was to determine
efficacy and patient adherence with adapalene 0.1%/benzoyl peroxide 2.5 % in patients with
moderate inflammatory acne between the ages of 12 and 20 years old. A total of 2,780 patients
were observed for 12 weeks within 314 dermatology centers throughout Germany. The
outcomes assessed within this study included skin irritation, tolerability, changes in severity of
acne, efficacy of treatment, and treatment adherence. Skin irritation was assessed using a scale
of none, mild, moderate, or severe to rate the degree of erythema, dryness, desquamation,
burning or stinging, and pruritis at each follow up visit. Adverse drug reactions were also noted
at each visit. Physician rated tolerability was assessed using a 4-item scale of very good, good,
satisfactory, or poor. Also, the Leeds Revised Acne Grading System was used to assess
changes in the severity of acne. Efficacy of treatment was assessed by physicians using
another 4-item scale of very good, good, satisfactory, and poor. Patients also assessed efficacy
of treatment using a 6-item scale of completely cured, marked improvement, moderate
improvement, slight improvement, no change, or worsened. Finally, treatment adherence was
assessed using a 4-item questionnaire at the final visit by asking the following questions: do you
remember the name of the (last) drug(s) you took, have you tolerated the(se) drug(s) well, have
you ever stopped taking the(se) drug(s) because you thought it would do more harm than good,
and have the(se) drug(s) been useful for you?
Ultimately, acne severity decreased from 4.8 ± 0.9 at baseline to 2.1 ± 1.6 at the end of
12 weeks based on the Leeds Revised Acne Grading System. Efficacy was rated by physicians
as good or very good in 79.2% of patients. Skin irritation was rated as none (19%), mild (51%),
moderate (24%), and severe (6%) among patients. Tolerability was rated as good or very good
by physicians for 82.8% of patients. Also, 63.2% of patients were considered adherent to
treatment based on the 4-item questionnaire. Finally, 82.3% of patients were either satisfied or
very satisfied with treatment, while physicians rated treatment as good or very good for 80.1%
of patients.
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Using the Johns Hopkins Research Appraisal Tool, this study was also deemed high
quality based on the consistent and generalizable results reported in this study. An adequate
sample size of 2,780 patients were also included within this study to support the high quality
rating. Definitive conclusions and recommendations are drawn from the study, suggesting the
safe and efficacious use of A-BP for the treatment of moderate inflammatory acne vulgaris.
Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
After critical appraisal, the included pieces of evidence were synthesized to identify
common themes. Various acne vulgaris treatments were presented throughout the literature,
with common themes of utilizing BP, adapalene, topical clindamycin, and systemic doxycycline.
Other common themes identified within the evidence were the use of acne measurement scales
to determine the severity of acne vulgaris and quality of life measurements.
Benzoyl Peroxide
The use of BP has been indicated for the treatment of acne vulgaris either alone (Asai et
al., 2015; Le Cleach et al., 2017; Yang et al., 2020) or in combination with other acne
treatments, such as adapalene, topical clindamycin, or systemic doxycycline (Asai et al., 2015;
Friedman et al., 2016; Gollnick, Friedrich, et al., 2015; Gollnick, Funke, et al., 2015; Le Cleach
et al., 2017; Nast et al., 2016; Zaenglein at al., 2016). Overall, BP alone is indicated for the
treatment of comedonal acne (Asai et al., 2015; Le Cleach et al., 2017). The use of BP in
combination with adapalene for mild and moderate acne was also evident within the literature
(Asai et al., 2015; Gollnick, Friedrich, et al., 2015; Gollnick, Funke, et al., 2015; Le Cleach et al.,
2017; Nast et al., 2016; Zaenglein et al., 2016). Similarly, BP in combination with topical
clindamycin for the treatment of mild and moderate acne was evident, however, fewer pieces of
evidence focused on this combination treatment compared to the combination of BP and
adapalene for mild and moderate acne (Asai et al., 2015; Nast et al., 2016; Zaenglein et al.,
2016). For severe acne, BP can be used in combination with both adapalene and systemic
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doxycycline (Asai et al., 2015; Le Cleach et al., 2017; Nast et al., 2016). Also, it appears BP in
combination with both adapalene and systemic doxycycline is indicated for treatment of very
severe acne (Nast et al., 2016). Formulations of BP vary, however, based on the literature it
appears BP 2.5% is preferred (Friedman et al., 2016; Gollnick, Friedrich, et al., 2015; Gollnick,
Funke, et al., 2015; Nast et al., 2016; Yang et al., 2020).
Adapalene
Adapalene can be utilized for the treatment of acne vulgaris either alone (Asai et al.,
2015; Nast et al., 2016) or in combination with other acne treatments, such as BP, topical
clindamycin, or systemic doxycycline (Asai et al., 2015; Friedman et al., 2016; Gollnick,
Friedrich, et al., 2015; Gollnick, Funke, et al., 2015; Nast et al., 2016). Adapalene was indicated
for the treatment of comedonal acne (Asai et al., 2015; Nast et al., 2016), as well as for mild and
moderate acne when combined with BP (Asai et al., 2015; Gollnick, Friedrich, et al., 2015;
Gollnick, Funke, et al., 2015; Nast et al., 2016). Also, for severe acne adapalene can be used in
combination with both BP and systemic doxycycline (Asai et al., 2015; Le Cleach et al., 2017;
Nast et al., 2016). Adapalene, systemic doxycycline, and BP were also indicated for the
treatment of very severe acne (Nast et al., 2016). Just like with BP, formulations of adapalene
can vary. Based on the evidence, adapalene 0.1% was the most commonly used agent
(Friedman et al., 2016; Gollnick, Friedrich, et al., 2015; Gollnick, Funke, et al., 2015; Nast et al.,
2016).
Topical Clindamycin
Topical clindamycin is another treatment option indicated for the treatment of acne
vulgaris. This medication is used in combination with BP to treat mild and moderate acne
vulgaris (Asai et al., 2015; Nast et al., 2016; Zaenglein et al., 2016). It is also mentioned that
antibiotics used for the treatment of acne should be used in conjunction with other medications
and never as monotherapy to decrease the risk of antibiotic resistance (Asai et al., 2015; Le
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Cleach et al., 2017; Nast et al., 2016; Zaenglein et al., 2016). Thus, this supports the previous
mentioned evidence of utilizing topical clindamycin with BP for acne vulgaris treatment.
Systemic Doxycycline
The use of systemic doxycycline is reserved for treating severe (Asai et al., 2015; Le
Cleach et al., 2017; Nast et al., 2016) and very severe acne (Nast et al., 2016). For severe
acne, doxycycline is combined with both BP and adapalene (Asai et al., 2015; Le Cleach et al.,
2017; Nast et al., 2016). This combination is also the same with very severe acne (Nast et al.,
2016). As mentioned previously for topical clindamycin, antibiotics should never be used as
monotherapy to decrease the risk of antibiotic resistance (Asai et al., 2015; Le Cleach et al.,
2017; Nast et al., 2016; Zaenglein et al., 2016). Thus, doxycycline combined with other acne
treatments is supported by the evidence. There was no specific recommended dosage
mentioned within the literature for the use of doxycycline.
Acne Measurement Scales
Ultimately, the evidence suggests there is no universally recommended grading scale for
acne vulgaris (Nast et al., 2016; Zaenglein et al., 2016). However, clinicians should personally
select and consistently use a grading system to determine changes over time and to measure
response to treatment (Asai et al., 2015; Nast et al., 2016; Zaenglein et al., 2016). The evidence
also suggests that patient self-assessed quality of life can be used to measure the impact acne
has on an individual’s life and well-being (Asai et al., 2015; Nast et al., 2016; Yang et al., 2020).
Similarly, Likert or Likert-type scales can be used as a type of patient self-assessment to
determine the severity of acne as perceived by the patient themselves (Gollnick, Friedrich, et
al., 2015; Gollnick, Funke, et al., 2015; Yang et al., 2020).
Best Practice Model Recommendation
The synthesis of evidence suggests that treatment agents vary for each classification of
acne vulgaris. For comedonal acne, it is recommended to use either BP 2.5% or adapalene
0.1%. For mild and moderate acne, treatment regimens are the same for both classifications.
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There was more evidence to suggest combination adapalene 0.1% and BP 2.5% is preferred,
however, there was some evidence to suggest combination BP 2.5% and clindamycin was also
effective. Based on the amount of available evidence, combination adapalene 0.1% and BP
2.5% should be utilized as first-line therapy, followed by BP 2.5% and clindamycin used as
second-line therapy. Finally, for severe and very severe acne, a combination of BP 2.5%,
adapalene 0.1%, and systemic doxycycline should be used for treatment. All medications
synthesized from the literature were reviewed using GoodRx to ensure they were in face costeffective options. Also, based on the evidence, patient self-assessment of quality of life and
acne severity should ultimately be measured.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
The purpose of this EBP project is to improve patient outcomes a cost-effective
treatment algorithm for the management of acne vulgaris. The goal of cost-effective treatment is
to reduce any financial barriers patients may face when obtaining treatment for acne vulgaris.
The implementation of this EBP project aims to improve patient quality of life. Treatment of acne
is important as patients with acne may experience issues with mental health disorders (Singam
et al., 2019), difficulty with emotion regulation (Cengiz & Gurel, 2020), as well as scarring and
poor self-esteem (Zaenglein et al., 2016), which all can impact a patient’s quality of life. Overall,
this practice change aims to combat these issues and to ultimately provide patient satisfaction
with acne treatment that will lead to an improved quality of life.
Setting and Participants
Implementation of this EBP project took place at a university student health center
located in Northwest Indiana. This particular student health center provides services that are
focused on delivering primary health care to students. Services include administration of
immunizations, wellness exams, and problem visits, among others. The clinic is staffed by a
physician, two FNPs, a psychiatric nurse practitioner, a registered nurse, a registered dietitian,
and a receptionist. One of the FNPs also serves as the health center director as well.
Permission for project implementation was granted by the health center director on April 15,
2020.
The population of interest for this project was adult college students aged 18 years and
older with a diagnosis of acne vulgaris. This served as the inclusion criteria for the project.
Participants were also required to be able to speak and understand both verbal and written
English to be included in this project. Participants that were excluded from the study included
patients younger than 18 years old, patients who were pregnant or breastfeeding, and patients
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with any type of cognitive impairment. Such participants were excluded from the project for
safety reasons.
Recruitment of participants began on September 21, 2020 and lasted until March 19,
2021. Participants for this project were recruited through multiple measures including the use of
a flyer (Appendix B) posted in the front lobby at the student health center, information sent to
students via email and posted to social media platforms from the official student health center
accounts, and by meeting with students virtually in the classroom setting. The social media
platforms utilized for recruitment included Facebook, Instagram, and Twitter. The information
sent to participants in the email and posted to social media is available in Appendix C. The
project manager did not have direct access to the student health center email and social media
accounts, so information was sent by the health center director who regularly manages these
accounts.
Pre-Intervention Group Characteristics
After completing recruitment activities, a total of 17 participants were initially recruited for
this project. Pre-intervention group characteristics of these participants were briefly analyzed
using descriptive statistics. Participant ages ranged from 18 to 24 years old with a mean age of
21.0 years (SD = 2.23). The majority of participants were female (64.7%), Caucasian (94.1%),
and single (94.1%). For highest level of education completed, 23.5% completed high school,
47.1% completed some college without receiving a degree, 23.5% had a Bachelor’s degree,
and 5.9% had a Master’s degree. For primary employment, 5.9% reported working full-time,
17.6% reported working part-time, and 76.5% identified themselves as students for their
employment status. Finally, 35.3% of participants reported their annual household income as
less than $19,999; 5.9% reported making between $20,000 and $34,999; 23.5% reported
making between $50,000 and $74,999; 23.5% reported making between $75,000 and $99,999;
and 11.8% reported making over $100,000.
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Prior to project implementation, the project manager also collected data from the student
health center’s electronic medical record (EMR) system to determine how acne vulgaris was
treated by healthcare providers in the past between August 2017 to July 2020. Overall, 23
charts were reviewed and these revealed inconsistency of acne vulgaris treatment during this
specified time period. Various treatment regimens were used, in varied dosages and
combinations, and included salicylic acid, BP, tretinoin, adapalene, topical clindamycin, topical
erythromycin, systemic minocycline, and systemic doxycycline. Acne severity levels were also
not consistently assigned to patients, in which only 22% of the 23 reviewed charts contained
documentation of an acne severity level of either mild or moderate.
Intervention
The intervention for this EBP project involved the use of a cost-effective treatment
algorithm for acne vulgaris by two FNPs at the student health center. This algorithm was
developed based on the synthesized evidence from the literature search as discussed above in
Chapter 2. A copy of the treatment algorithm is included in Appendix D. The algorithm has three
first-line treatment categories and one second-line treatment category based on the levels of
acne severity identified by the modified IGA scale. The IGA scale is currently recommended by
the United States Department of Health and Human Services (USDHHS) Food and Drug
Administration (FDA) Center for Drug Evaluation and Research (CDER) for use in clinical trials
to measure acne severity (FDA, 2018). A sample IGA scale was published in a draft guidance
for acne vulgaris treatment by the USDHHS FDA CDER in 2005 which contains five levels of
acne severity, including clear, almost clear, mild, moderate, and severe (FDA, 2005). The IGA
scale used for the intervention in this project was modified from the USDHHS FDA CDER
sample IGA scale to include a sixth treatment category, very severe, as the synthesized
evidence from the literature search provided specific recommendations for the treatment of very
severe acne. Modifying the scale to include this category would allow for consistent treatment
across the entire spectrum of acne severity. This modified IGA scale can be found in Appendix
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E. A detailed policy on how to implement the treatment algorithm was also developed for
provider use and is available in Appendix F. Dosing information for each medication was also
included within both the treatment algorithm and policy for provider reference. In addition,
copies of the treatment algorithm and policy were provided to each FNP. A copy of the
treatment algorithm was also posted in the medication room at the student health center for
easy reference.
During the recruitment process, potential participants were asked to contact the project
manager in an effort to explain the project in detail and enroll the participants in the project.
After explaining the project in depth, participants were asked if they would like to enroll in the
project and schedule an appointment at the student health center. In an effort to compare data
between participants who received the intervention and those who did not, the project manager
decided to use two participant groups to obtain as much data as possible. Participants who
agreed to schedule an appointment at the student health center made up the intervention group.
Participants who declined treatment at the student health center were asked to enroll in the
project to serve as a comparison group. Both groups of participants were asked to fill out an
informed consent document (Appendix G), demographic form (Appendix H), and the baseline
Acne-QoL questionnaire. These documents were sent to the participants via email.
For the participants in the intervention group, the next step was to schedule an
appointment at the student health center to have their acne treated. At the student health
center, participants would be seen by one of the FNP providers who would then examine the
participant and grade his or her acne severity by using the modified IGA scale. Providers
documented the acne severity for participants in the student health center’s EMR. Based on the
results from the modified IGA scale, the provider would then follow the treatment algorithm to
prescribe the appropriate medications. The student health center was able to keep BP,
clindamycin phosphate, and doxycycline stocked on hand for participants to take home
immediately after their visit, if wished to do so. Adapalene was the only medication that was
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unable to be kept at the student health center and a prescription was provided for participants to
fill at a pharmacy of their choice instead. Prescriptions for the other medications were also
available to participants if they did not choose to purchase them directly from the student health
center. Participants were also instructed on the appropriate use of their medications during their
visit, including dosage instructions, time of day to use the medication, and potential side effects.
Follow up for the intervention group was conducted 6 weeks following each individual
participant’s initial visit at the student health center. Follow-up for participants in the comparison
group also took place after 6 weeks from initially filling out their baseline Acne-QoL
questionnaire. The follow-up Acne-QoL questionnaire was sent to each individual participant’s
email to fill out and send back to the project manager. Participants were also contacted by
phone to remind them to complete the 6-week questionnaire. Participants were encouraged to
ask any questions they had during these follow-up periods as well.
Comparison
Comparisons for the project were made between the intervention group and comparison
group after the 6-week period. These comparisons were made based on the data collected from
the baseline and 6-week Acne-QoL questionnaires. The intervention group also served as its
own comparison group, as comparisons were made based on the data from the baseline and 6week Acne-QoL questionnaires completed within this group. These comparisons aim to identify
any significant changes that may have occurred due to the intervention of treating acne with the
treatment algorithm.
Outcomes
The primary outcome selected for this project was patient self-assessment of quality of
life as measured by the Acne-QoL questionnaire. The project manager obtained permission to
use this questionnaire for the duration of the project. This questionnaire was developed for use
in clinical trials to assess the quality of life of patients between the ages of 13-35 years old who
have facial acne. The questionnaire has also been indicated for use in the clinic or dermatology
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office settings (Girman et al., 2003). The Acne-QoL is a self-administered, 19-item questionnaire
that focuses on four specific areas relating to how facial acne impacts quality of life and how
severe the patient perceives his or her acne. These four areas include self-perception, roleemotional, role-social, and acne symptoms. The self-perception domain involves asking
questions focused on feelings of self-consciousness, unattractiveness, or dissatisfaction with
appearance. The domain of role-emotional assesses the emotional effect acne has on the
participant. Role-social focuses on questions that determine the impact acne has on the
participant’s social relationships. Finally, the acne symptoms domain assesses the physical
symptoms caused by acne (Girman et al., 2003). There are five questions asked within each
domain, except role-social in which only four questions are asked. Responses for the domains
self-perception, role-emotional, and role-social range from 0 to 6 as follows: 0) extremely, 1)
very much, 2) quite a bit, 3) a good bit, 4) somewhat, 5) a little bit, and 6) not at all. Responses
to the domain acne symptoms ranges from 0 to 6 as well, however the responses are slightly
different compared to the other domains and are as follows: 0) extensive, 1) a whole lot, 2) a lot,
3) a moderate amount, 4) some, 5) very few, and 6) none. To score the questionnaire, the
questions associated with each domain are added together so each participant has a total of
four scores, one for each domain. The domains of self-perception, role-emotional, and acne
symptoms are scored out of 30 points, while role-social is scored out of 24 points. Higher scores
within each domain are associated with an increased quality of life (Girman et al., 2003). A copy
of the Acne-QoL questionnaire can be found in Martin et al. (2001).
The Acne-QoL has been measured for both validity and reliability in a previous study.
According to Fehnel et al. (2002), the Acne-QoL demonstrated reliability via internal consistency
in which the domains of self-perception, role-emotional, and role-social were measured across
three time-points using Cronbach’s alpha and results ranged from 0.87 to 0.96. The acne
symptoms domain was also measured in this way and ranged from 0.77 to 0.86. Results greater
than 0.7 are considered acceptable levels of reliability, however, results closer to 1.0
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demonstrate higher levels of reliability. Fehnel et al. (2002) also mentioned convergent validity
of the Acne-QoL questionnaire was demonstrated with evidence of modest negative correlations
when compared to total lesion counts and a facial acne global assessment scale. These results
suggested that clinician reported acne severity was associated with patient reported quality of
life.
In addition to the Acne-QoL questionnaire, providers measured acne severity using a
modified IGA scale. This scale was modified to include a very severe category of acne (Grade
5), as the highest grade on the original IGA scale is severe (Grade 4). The original IGA scale
has not been tested for validity. However, this scale does have a moderate intra-rater reliability
(K = 0.606) and a fair inter-rater reliability (K = 0.3119) (Agnew et al., 2016). Finally,
demographic data for this project was also collected by having participants fill out a
demographic form during their baseline visit, prior to being seen by the provider.
Following implementation of the project, data analysis was completed using IBM
Statistical Package for Social Sciences (SPSS) Base 25. Descriptive statistics including means
and frequencies were used for the demographic characteristics of participants. Demographic
data were also compared between the two groups via Chi-square tests of independence and
independent-samples t test. Pre- and post-intervention data for the intervention group and
comparison group were analyzed using paired-samples t tests. Pre- and post-intervention data
between both the intervention and comparison groups were analyzed using a mixed-design
analysis of variance (ANOVA) test.
Time
This project had a rolling recruitment of participants which lasted from September 21,
2020 and lasted until March 19, 2020. Project implementation began on September 16, 2020
and follow up with participants lasted until April 30, 2021. This period of time allowed for an
adequate number of participants to be enrolled into the project to ensure ample data was
collected for data analysis.
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Protection of Human Subjects
Human subjects were protected throughout the duration of the project. An online
training course was completed by the project manager on April 7, 2020 through the
Collaborative Institutional Training Initiative (CITI) titled Social Behavioral Educational
Researchers. A certificate of completion was provided by CITI and is available in Appendix I. An
expedited application through the Institutional Review Board (IRB) at Valparaiso University was
also completed. After review of the application, exempt approval for the project was obtained
from the IRB on September 9, 2020. Written consent was obtained from all participants after
reviewing the purpose of the project, risks, benefits, confidentiality, and voluntary participation.
All data collected for the duration of the project was kept secured via a lockbox and password
protected computer. A code sheet was also utilized to help protect the participants identities.
This code sheet, along with documents containing participants personal information, were
destroyed at the completion of this project.
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to implement a cost-effective treatment algorithm at
the university student health center to manage acne vulgaris in adult college students. The
primary outcome of quality of life was measured using participant self-reported assessments via
the Acne-QoL questionnaire. This outcome was measured at baseline visits and during a followup period 6-weeks after baseline measurements.
Participants
Size and Characteristics
The pre-intervention group consisting of 17 participants completed baseline
measurements of the Acne-QoL questionnaire as identified in Chapter 3. Of these 17
participants, 14 ultimately completed the 6-week Acne-QoL questionnaire for the follow-up
period, resulting in an attrition rate of 17.6%. Ten of these participants were included in the
intervention group, while four participants were included in the comparison group. Demographic
data were collected and analyzed using descriptive statistics for the 14 total participants in this
project. Demographic data collected from participants included age, gender, ethnicity/race,
marital status, highest level of education completed, employment status, and annual household
income. Demographic data between the intervention group and comparison group were also
analyzed using inferential statistics to determine if there were any significant differences
between the two groups.
Intervention Group
Participant ages ranged from 18 to 24 years old with a mean age of 21.20 years (SD =
2.44). The majority of participants were male (60%) and Caucasian (90%). Also, the majority of
participants reported their marital status as single (90%), had already completed some college
without yet obtaining a degree (40%), reported being a student for their primary employment
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status (70%), and made an annual household income of less than $19,999 (40%). A summary
of the detailed descriptive statistics of the participants within the intervention group is included in
Table 4.1.
Acne severity based on provider assessments using the modified IGA scale for this
group included: 1) almost clear (20%), 2) mild (30%), 3) moderate (30%), and 4) severe (20%).
None of the participants had acne classified as very severe (Grade 5) based on the modified
IGA scale. For participants with acne categorized as almost clear, 100% received treatment with
topical BP. For those with mild acne, 33.3% received treatment with combination topical BP and
adapalene and the remaining 66.6% received treatment with combination topical BP and topical
clindamycin. For those with moderate acne, 100% received treatment using combination topical
BP and topical clindamycin. Finally, those with severe acne received the only treatment option
available for this level of severity on the treatment algorithm, which consisted of combination
topical BP, topical adapalene, and systemic doxycycline (100%).
Comparison Group
Participant ages ranged from 20 to 23 years old with a mean age of 21.75 years (SD =
1.26). All participants were female (100%), Caucasian (100%), and single (100%). The majority
of participants had a high school diploma or GED reported as their highest level of education
completed (50%), reported being a student for their primary employment status (75%), and
made an annual household income of less than $19,999 (50%). The detailed descriptive
statistics of the participants are summarized in Table 4.1.
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Table 4.1
Demographic Characteristics

Intervention Group (n = 10)

Comparison Group (n = 4)

n (%)

n (%)

21.20/2.44

21.75/1.25

18 – 24

20 – 23

Male

6 (60)

0 (0)

Female

4 (40)

4 (100)

Caucasian

9 (90)

4 (100)

Asian

1 (10)

0 (0)

African-American

0 (0)

0 (0)

Hispanic

0 (0)

0 (0)

Single

9 (90)

4 (100)

Married

1 (10)

0 (0)

Divorced

0 (0)

0 (0)

Widowed

0 (0)

0 (0)

High school/GED

2 (20)

2 (50)

Some college

4 (40)

1 (25)

Associate’s degree

0 (0)

0 (0)

Demographic

Age
Mean/SD
Range
Gender

Race/Ethnicity

Martial Status

Highest level of education

ACNE VULGARIS TREATMENT ALGORITHM

41

Bachelor’s degree

3 (30)

1 (25)

Master’s degree

1 (10)

0 (0)

Doctoral degree

0 (0)

0 (0)

Full time

1 (10)

0 (0)

Part time

2 (20)

1 (25)

Unemployed

0 (0)

0 (0)

Student

7 (70)

3 (75)

Homemaker

0 (0)

0 (0)

Retired

0 (0)

0 (0)

Self-employed

0 (0)

0 (0)

Unable to work

0 (0)

0 (0)

Less than $19,999

4 (40)

2 (50)

$20,000 - $34,999

1 (10)

0 (0)

$35,000 - $49,999

0 (0)

0 (0)

$50,000 - $74,999

2 (20)

1 (25)

$75,000 - $99,999

3 (30)

0 (0)

Over $100,000

0 (0)

1 (0)

Employment Status

Annual Household Income
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Changes in Outcomes
This EBP project addressed the following PICOT question: in adult college students
diagnosed with acne vulgaris at the university’s student health center (P), how does a costeffective acne treatment algorithm (I) compared to current practice without an algorithm (C)
impact participant quality of life measured by the Acne-QoL questionnaire (O) over a 6-week
period (T)? The primary outcome measured for this project was participant quality of life as
measured by the Acne-QoL questionnaire.
Statistical Testing and Significance
For data entry and analysis, SPSS Version 25 was utilized. Paired-sample t tests were
used to compare the mean baseline and 6-week scores from each domain of the Acne-QoL
questionnaire for both the intervention group participants and comparison group participants. A
mixed-design ANOVA was also utilized for each domain category to compare the mean
baseline and 6-week Acne-QoL questionnaire scores between the intervention group and
comparison group. To conclude the data analysis, Cronbach’s alpha was calculated to
determine the reliability of the Acne-QoL questionnaire by measuring baseline and 6-week
participant responses within all four domains. Statistical significance for all analyses was
determined as p < .05.
Findings
Participants
An independent-samples t test was used to compare the mean ages of both the
intervention group and comparison groups. No statistically significant difference was found
between the two groups (t (12) = -.422, p = .681). Also, chi-square tests of independence were
used to compare differences in gender and race between both groups. There was a statistically
significant difference in gender between the intervention group and comparison group (χ 2 (1) =
4.2, p = .04). There was no statistically significant difference in race between the intervention
and comparison group (χ2 (1) = .431, p = .512).
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Primary Outcome
A paired-samples t test were calculated to compare the mean baseline and 6-week
scores from each domain of the Acne-QoL questionnaire for the intervention group. For the selfperception domain, the mean baseline score was 18.90 (SD = 7.17) and the mean 6-week
score was 23.80 (SD = 7.39). A statistically significant increase in scores from baseline to 6
weeks was found (t (9) = -3.171, p = .011). For the role-emotional domain, the mean baseline
score was 18.10 (SD = 7.03) and the mean 6-week score was 23.70 (SD = 6.39). A statistically
significant increase in scores from baseline to 6 weeks was also found for this domain (t (9) = 2.675, p = .025). For the role-social domain, the mean baseline score was 20.60 (SD = 3.78)
and the mean 6-week score was 20.80 (SD = 5.18). A significant difference was not found
between the means for this domain (t (9) = -.165, p = .872). Finally, for the acne symptoms
domain, the mean baseline score was 17.60 (SD = 3.92) and the mean 6-week score was 21.70
(SD = 5.62). A statistically significant increase in scores from baseline to 6 weeks was found (t
(9) = -3.48, p = .007). A visual representation of these findings is included in Figure 4.1.
A paired-samples t test was also calculated to compare the mean baseline and 6-week
scores from each domain of the Acne-QoL questionnaire for the comparison group as well. For
the self-perception domain, the mean baseline score was 8.50 (SD = 10.47) and the mean 6week score was 20.75 (SD = 7.59). No statistical significance was found between these scores
(t (3) = -3.174, p = .05). For the role-emotional domain, the mean baseline score was 9.25 (SD
= 10.53) and the mean 6-week score was 19.0 (SD = 9.56). No statistical significance was
found between these scores (t (3) = -1.928, p = .149). For the role-social domain, the mean
baseline score was 15.50 (SD = 5.75) and the mean 6-week score was 18.25 (SD = 7.63). No
statistical significance was found between these scores (t (3) = -1.117, p = .345). Finally, for the
acne symptoms domain, the mean baseline score was 13.25 (SD = 8.02) and the mean 6-week
score was 18.75 (SD = 2.63). No statistical significance was found between these scores either
(t (3) = -1.718, p = .184). A visual representation of these findings is included in Figure 4.2.
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Figure 4.1
Intervention Group Mean Scores Over Time
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Figure 4.2
Comparison Group Mean Scores Over Time
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To analyze the differences between the intervention and comparison groups, a mixeddesign ANOVA was calculated for each domain on the Acne-QoL questionnaire. For the selfperception domain, total mean scores for both groups were 15.93 (SD = 9.20) at baseline and
22.79 (SD = 7.35) at 6-weeks. For this domain, there was no statistically significant interaction
between time of measurement on the Acne-QoL questionnaire and group type on the overall
mean self-perception scores (F (1,12) = 4.26, p = .061). There was also no statistically
significant difference between group types (F (1,12) = 2.628, p = .131). However, the effect of
time did show a statistically significant difference in mean self-perception scores at the different
time points for both groups (F (1,12) = 25.168, p < .001).
For the role-emotional domain, total mean scores for both groups were 15.57 (SD =
8.78) at baseline and 22.36 (SD = 7.37) at 6-weeks. There was no statistically significant
interaction between time of measurement and group type on the overall mean role-emotional
scores (F (1,12) = .842, p = .377). There was also no statistically significant difference found
between group types either (F (1,12) = 2.944, p = .112). A statistically significant difference was
found for the effect of time for both groups in this case (F (1,12) = 11.522, p = .005).
For the role-social domain, total mean scores for both groups were 19.14 (SD = 4.81) at
baseline and 20.07 (SD = 5.78) at 6-weeks. There was also no statistically significant interaction
between time of measurement of the Acne-QoL questionnaire and group type on the overall
role-social scores (F (1,12) = 1.091, p = .317). No statistically significant difference was found
between group types (F (1,12) = 1.852, p = .199) or for the effect of time as well (F (1,12) =
1.46, p = .250).
Finally, for the acne symptoms domain, total mean scores for both groups were 16.36
(SD = 5.44) at baseline and 20.86 (SD = 5.04) at 6-weeks. This domain followed suite with the
first two domains, in that there was no statistically significant interaction between time of
measurement on the Acne-QoL questionnaire and group type on the overall mean scores (F
(1,12) = .271, p = .612). There was also no statistically significant difference between group
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types (F (1,12) = 1.784, p = .206). However, the effect of time did show a statistically significant
difference in mean acne symptoms scores at the different time points for both groups (F (1,12) =
12.746, p = .004).
Overall comparisons of mean domain scores between the intervention group and
comparison group can be found in Figure 4.3, Figure 4.4, Figure 4.5, and Figure 4.6.
Acne-QoL Reliability
To measure the reliability of the Acne-QoL questionnaire, Cronbach’s alpha was
calculated for each of the four domains using scores from both the baseline and 6-week
measurements. Overall, high levels of internal consistency were found for all four domains for
both the baseline and 6-week measurements. The following Cronbach’s alpha levels were found
for the baseline measurements for each domain: self-perception (0.96), role-emotional (0.95),
role-social (0.82), and acne symptoms (0.79). Six-week measurements included: self-perception
(0.96), role-emotional (0.92), role-social (0.97), and acne symptoms (0.81).
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Figure 4.3
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Figure 4.4
Role-Emotional Domain Mean Scores
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Figure 4.5
Role-Social Domain Mean Scores
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Figure 4.6
Acne Symptoms Domain Mean Scores
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CHAPTER 5
DISCUSSION
The purpose of this EBP project was to improve participant quality of life through the
implementation of a cost-effective treatment algorithm for the management of acne vulgaris in
adult college students. This project served to answer the following PICOT question: in adult
college students diagnosed with acne vulgaris at the university’s student health center (P), how
does a cost-effective acne treatment algorithm (I) compared to current practice without an
algorithm (C) impact participant quality of life measured by the Acne-QoL questionnaire (O) over
a 6-week period (T)? In this chapter the project findings will be discussed and interpreted, the
strengths and limitations of the project will be explored, and implications for future practice will
be provided.
Explanation of Findings
Overall, project findings supported the effectiveness of using a cost-effective treatment
algorithm for the management of acne vulgaris in adult college students. Results were
consistent with previous uses of the Acne-QoL questionnaire in the literature, in which statistical
significance was yielded for the self-perception, role-emotional, and acne symptoms domains
supporting improvement of quality of life. The only exception to this were the findings for the role
social domain, in which statistical significance was not found. Participant findings and the
primary outcome of quality of life will be discussed further in this section. A discussion regarding
the findings relating to reliability of the Acne-QoL questionnaire will also be provided.
Participant Findings
Demographic data for participants were analyzed to determine if any significant
differences existed between the intervention group and comparison group. Overall, there were
no statistically significant differences between the two groups regarding age (p = .681) or race
(p = .512). Mean age for the intervention group was 21.20 years (SD = 2.44) and was 21.75
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years (SD = 1.26) for the comparison group. The predominant race for participants was
Caucasian for both the intervention group (90%) and comparison group (100%). A statistically
significant difference did exist between the two groups regarding gender (p = .04) in which the
intervention group (n = 10) comprised of six males (60%) and four females (40%) did differ from
the comparison group (n = 4) which was made up of entirely female participants (100%),
suggesting the groups did differ from one another. This is likely the result of having such a small
sample size of 14 total participants and a larger sample size would most likely lead to more
equal gender distributions between each group.
Quality of Life
Based on the paired-samples t test that was calculated for the intervention group, a
statistically significant increase in quality of life was found for three of the four domains on the
Acne-QoL questionnaire after completing 6 weeks of treatment. Participants mean scores
significantly increased for the self-perception (p = .011), role-emotional (p = .025), and acne
symptoms (p = .007) domains. For the role-social domain, there was no statistically significant
increase in quality of life for this group (p = .872). However, the role-social domain did have the
highest mean at baseline (M = 20.60, SD = 3.78) compared to the other four domains, which
suggests participants may have already been relatively satisfied with their quality of life in this
particular domain prior to receiving treatment. The increase in quality of life for the selfperception, role-social, and acne symptoms domains is consistent with the findings by Fehnel et
al. (2002); however, significant results were also noted for the role-social domain within this
study. This inconsistent finding for the role-social domain may be due to the project’s smaller
sample size, as the study by Fehnel et al. (2002) was comprised of a much larger sample size
of 591 patients. The paired-samples t test was also used to compare the mean baseline and 6week Acne-QoL domain scores for the comparison group as well. While there were increases in
the overall mean scores for each domain, none of these increases were statistically significant.
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Overall, there was no statistically significant interaction between the time of
measurement (baseline and 6 weeks) and group type (intervention and comparison) for any of
the four domains on the Acne-QoL questionnaire after calculating a mixed-design ANOVA.
There was also no statistically significant difference in the mean scores for each domain
between the intervention group and comparison group, regardless of time. However, there was
a statistically significant increase in mean scores over time for both groups in the self-perception
(p < .001), role-emotional (p = .005), and acne symptoms (p = .004) domains. There was no
statistically significant increase in mean scores over time for either group in the role-social
domain (p = .250). These results suggest that group type did not have an influence on the
increased quality of life for participants, as the total mean scores for both the intervention group
and comparison group improved after 6 weeks. However, it is worth mentioning that after
comparing the mean scores between the two groups, the intervention group did have higher
mean scores after 6 weeks for each domain as depicted in Figure 4.3, Figure 4.4, Figure 4.5,
and Figure 4.6. Again, while there was no statistically significant difference between the
intervention group and comparison group, the findings for the intervention group do suggest
some clinical significance.
The comparison groups increase in scores could have been caused if participants
possibly receiving care elsewhere during the project’s timeline. During recruitment, participants
were not assessed as to whether they were receiving concurrent treatment for acne vulgaris
from another source or if they had planned to receive treatment during the 6-week time frame. If
participants within this group were undergoing treatment during the project time period, this may
have influenced the increase in Acne-QoL questionnaire scores. The increase in scores could
also be related to participant self-awareness of acne during the project time period in which
participants may have been taking proactive measures to combat acne due to their participation
in the project. Proactive measures to combat acne could include the use of over-the-counter
(OTC) acne medications, facial cleansers, and overall better hygiene techniques, that may have
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overall lead to an improvement in the comparison groups acne, leading to increased scores on
the Acne-QoL questionnaire after 6 weeks.
Acne-QoL Reliability
Cronbach’s alpha calculations were used to determine the internal consistency of the
four domains featured within the Acne-QoL questionnaire. Overall, high levels of internal
consistency were found for all domains for both the baseline and 6-week Acne-QoL
questionnaire measurements. For the baseline measurement, self-perception was noted as
0.96, role-emotional as 0.95, role-social as 0.82, and acne symptoms as 0.79. For the 6-week
measurement, self-perception was 0.96, role-emotional was 0.92, role-social was 0.97, and
acne symptoms was 0.81. These results demonstrate high levels of internal consistency as
reliable results should be greater than 0.7, with results closer to 1.0 demonstrate an even higher
level of reliability. These findings are consistent with the literature in which Fehnel et al. (2002)
reported Cronbach’s alpha ranges of 0.87 to 0.96 for the self-perception, role-emotional, and
role-social domains of the Acne-QoL questionnaire and a range of 0.77 to 0.86 for the acne
symptoms domain.
Strengths and Limitations of the DNP Project
Strengths
One of the main strengths of this project was the ability to provide affordable
medications to college students. In general, medications for skin care can be costly, so one of
the main goals for this project was to select medications that were relatively affordable for
patients. This is especially important for college students who may already have a limited
financial budget. The ability to keep these medications on hand at the student health center also
helped to ensure patients had immediate access to the required treatment regimens. Overall,
utilizing recommended agents that are affordable for college students and keeping medication
on hand can help to eliminate any financial barriers the students may face and increases access
to treatment for acne vulgaris.

ACNE VULGARIS TREATMENT ALGORITHM

56

The use of the revised Iowa Model also served as a strength throughout the duration of
this project. The model was utilized as a guide for the development, implementation, and
sustainability of this EBP project. This model involves seven main steps including (a) identifying
the triggering issue or opportunity, (b) stating the question or purpose, (c) forming a team, (d)
assembling, appraising, and synthesizing the body of evidence, (e) designing and piloting the
practice change, (f) identifying and sustaining the practice change, and (g) disseminating the
results (Melynk & Fineout-Overholt, 2019). Overall, this model served as a good fit throughout
the entire duration of the project. The simplicity and easy-to-follow steps within the revised Iowa
Model were helpful for the project manager as a novice to the EBP project process. The stop
points and feedback loops within the model also helped serve as a guide to ensure the project
stayed on track and remained true to the intended purpose.
Another strength of this project was the positive response, support, and receptiveness of
using the acne treatment algorithm by the FNPs. The health center director, who was also one
of the FNPs who helped implement the treatment algorithm, identified and recognized the need
for simplified and consistent management of acne vulgaris at the student health center. The
internal identification of the need to change practice at the student health center helped to
ensure that enough time and dedication were provided to implement the project to its full extent.
Both FNPs were very helpful throughout the implementation process and very receptive to the
practice change. The rest of the office staff at the student health center were also very
supportive of the practice change. The office staff were very helpful in ensuring participants
scheduled their appointments and provided discussions with participants regarding any
concerns they may have had regarding their insurance coverage of the office visit. Overall, the
staff receptiveness allowed for a smooth transition for the change in practice and helped
promote the success of this project. One of the FNPs at the student health center also stated to
the project manager that she plans to continue using the treatment algorithm and that she has
heard many students state they were satisfied with their acne treatment. The positive response
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noted throughout the duration of this project will hopefully allow for long lasting sustainability in
the future.
Limitations
The main limitation encountered during this project was the small sample size of
participants. Recruitment efforts were made to reach virtually all students on campus, however,
buy-in to the project was very low. Originally, there were only six participants who were
interested in the project, with five completing both the baseline and 6-week Acne-QoL
questionnaires. This limited amount of data was insufficient to run data analysis reports in
SPSS, so further recruitment was necessary to gather an ample amount of data. Original
recruitment efforts to reach potential participants consisted of displaying a poster at the student
health center, in various academic buildings throughout campus, and in the main student center
on campus; an email sent to 2,881 students on campus; and project information posts to
Facebook, Twitter, and Instagram. After deeming it necessary to recruit more participants,
another email was sent to students in an attempt to enroll more participants in the project. In
addition to this, the project manager met with students in the classroom setting to discuss the
project in more detail and to answer any questions potential participants had. After meeting with
the participants in the classroom setting, a Google Form was sent to all students in the class
with questions related to their interest in participating in the project. If the students answered
that they were interested in the project, the Google Form prompted them to fill out the
demographic form to get the enrollment process started. The project manager then reviewed
these responses and contacted the participants to fill out the informed consent document and
the baseline Acne-QoL questionnaire, which were sent to participants via email. Participants
were then assisted to schedule an appointment at the student health center. This process
allowed for the addition of 11 new participants to the project.
Another limitation to this project was the limited time students spent on campus due to
COVID-19 restrictions. Many students were completing remote learning during the fall and
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spring semesters and were not physically on campus, limiting the number of walk-in
appointments at the student health center. There was also an extended 2-month break between
semesters that was implemented due to COVID-19 that further limited student presence on
campus. Telehealth visits were utilized at the student health center to reach students that were
off campus during these times, however, accurate physical assessment of acne vulgaris is
limited when using telehealth measures compared to the assessments that take place during inperson visits. This project may have been able to reach a larger number of participants if it was
implemented at a different period in time.
One final limitation of this project were the costs associated with the student health
center visits. Participants enrolled in the student health center insurance plan were not billed for
their visit at the student health center, however, those with other insurance plans did have
associated costs such as co-pays or deductibles. Some participants also stated the student
health center did not accept their insurance plan; thus, they would be personally responsible for
all costs associated with the appointment. This ultimately limited participation for the project as
multiple students verbalized to the project manager that they did not wish to participate in the
project if they had to pay any out-of-pocket costs for the visit.
Implications for the Future
The findings from this EBP project have provided valuable information for the advanced
practice nursing profession related to the management of acne vulgaris in primary care settings.
Implications regarding practice, EBP model, research, and education will be discussed in detail.
These implications can be used to guide and improve future EBP projects and practice changes
regarding the management of acne vulgaris.
Practice
Best practice recommendations for the cost-effective management of acne vulgaris
suggest that treatment agents vary depending on the severity level of acne. It is also
recommended to have patients complete self-assessments of quality of life to determine the

ACNE VULGARIS TREATMENT ALGORITHM

59

effectiveness of treatment regimens. Based on these recommendations, a cost-effective
treatment algorithm was developed to manage acne vulgaris in adult college students and the
Acne-QoL questionnaire was selected as an appropriate tool to measure participant quality of
life. The implementation of this project became standard practice at the university student health
center, with the hopes this practice change will be sustained into the future. Sustainability was
supported through the development of a policy and by providing copies of the acne treatment
algorithm to the FNPs employed at the student health center. Unfortunately, copyright laws were
in place that prevent reproduction of the Acne-QoL questionnaire for use at the student health
center, leaving the health center without the means necessary to measure patient quality of life
in the same way this project did. However, other measurement tools are available for use and
have been mentioned in the literature such as the Acne-Q4 or CADI (Asai et al., 2015). Overall,
the use of a treatment algorithm to provide cost-effective, consistent management of acne
vulgaris and the use of patient self-assessments of quality of life are encouraged for all primary
care offices to provide best practice care to patients.
Implications for future EBP projects can benefit from a few key changes. Future projects
would benefit from a larger sample size to better generalize findings to the general population.
A comparison group would also not be necessary for implementing future projects and was only
utilized in this project due to limited student buy-in to receiving treatment at the student health
center. If a comparison group is utilized in future projects, it would also be beneficial to assess
potential participants if they are currently receiving acne treatment elsewhere or plan to receive
treatment throughout the duration of the project prior to including these participants in the
project. Comparison groups should also be assessed as to any changes they have made in
their skin care routine throughout the duration of the project. The original plans for this project
also involved having participants return to the student health center after 6 and 12 weeks of
treatment to have one of the FNPs reassess their acne severity using the modified IGA scale to
determine if provider-assessed severity levels had changed over time. These plans were no
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longer feasible due to the limited student buy-in to the project, and a 6-week follow-up period
with no provider-assessments of acne was utilized instead. Including provider-assessments of
acne severity will provide another quantitative measure to determine if acne is truly improving or
not, which is recommended throughout the literature (Asai et al., 2015; Nast et al., 2016;
Zaenglein et al., 2016). Also, incorporating a time frame of at least 12 weeks would allow ample
time to determine if a particular treatment regimen is working for the participant. The follow-up
appointment taking place at 6 weeks also allows for the opportunity to change medications if
necessary if there is no improvement in the participant’s acne. Overall, the inclusion of providerassessment of acne severity and increasing the project timeline to 12 weeks would also be
beneficial for future projects.
EBP Model
The revised Iowa Model was utilized as a guide for the development, implementation,
and sustainability of this EBP project. The seven steps outlined within this model helped serve
as a guide to ensure the project stayed on track and remained true to the intended purpose. The
simplicity and easy-to-follow steps within the revised Iowa Model helped guide the novice
project manager throughout the entire EBP project process. The ease of use and detailed steps
outlined within the revised Iowa Model allows the model to be utilized by both novice and expert
clinicians. Future projects can benefit from utilizing the revised Iowa Model for a variety of
different project topics and populations.
Research
Further research is needed to explore the use of a cost-effective treatment algorithm in
other settings, such as the dermatology specialty setting. A dermatology setting may provide a
larger sample size of patients with acne vulgaris for implementation of the algorithm, which may
lead to more generalizable results. Girman et al. (2003) also states the Acne-QoL questionnaire
is appropriate for dermatology specialty settings. The dermatology specialty setting would also
be appropriate to evaluate other treatment options, regardless of cost, such as isotretinoin.
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Isotretinoin was another medication commonly referenced in the literature for use of severe
acne vulgaris. This medication is typically prescribed by dermatologists and is rather costly,
which is why it was excluded from this project. However, research on the impact other treatment
options for acne vulgaris have on patient quality of life would be beneficial. Additional research
should also focus on adolescent and middle-aged adult populations as well, as acne typically
begins in adolescence and can continue into adulthood (Pandis, 2020; Zaenglein et al., 2016).
Education
Education is an important component advanced practice nurses need to address with
their patients. Participants in this project were educated about how to use the selected
medications, potential side effects of the medications, the purpose of therapy, and any
appropriate follow-up times. Education about how and when to use selected medications is very
important as topical medications may need to be used during certain times of the day and may
also need to be used before or after another topical medication. Not only is patient education
important, but provider education about acne vulgaris is equally important and should be
implemented as well. For this project, FNPs were educated on how to properly assess acne
vulgaris using the modified IGA scale and how to appropriately manage acne based on the
identified severity level using the treatment algorithm. FNPs were educated that the treatment
algorithm was developed based on the best practice recommendations identified in the
literature. Education for providers allows for familiarity with managing acne vulgaris so patients
can receive quality, high-level care.
Conclusion
Results from this project support the effectiveness of implementing a cost-effective
treatment algorithm for the management of acne vulgaris in adult college students to improve
patient quality of life. Statistical significance was found for three of the four Acne-QoL domains
which shows an improvement in quality of life was achieved for those who received treatment
with the treatment algorithm at the student health center. While there was no statistically
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significant difference between the intervention group and comparison group, the results are still
relevant to the overall clinical significance of improving quality of life among patients.
Sustainability of this project was discussed with the student health center director to allow for
the continued use of the treatment algorithm for future students seen at the health center for
acne vulgaris. Overall, the development of this treatment algorithm and the use of the Acne-QoL
questionnaire has patient interests in mind to ensure consistent, cost-effective, and best
practice care is provided to improve patient quality of life.
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Appendix A
Appraisal of Evidence

Citation (APA)

Purpose

Asai, Y.,
Baibergenova, A.,
Dutil, M., Humphrey,
S., Hull, P., Lynde,
C., Poulin, Y.,
Shear, N. H., Tan,
J., Toole, J., & Zip,
C. (2015).
Management of
acne: Canadian
clinical practice
guideline. Canadian
Medical Association
Journal, 188(2),
118-126.

Provide
recommendations
for the evaluation
and treatment of
acne vulgaris
based on severity
(comedonal acne,
mild
papulopustular,
moderate
papulopustular,
and severe
papulopustular/no
dular acne).

Design

Sample

Measurement/
Outcomes

Results/Findings

Level/
Quality

Clinical
Practice
Guideline

Pediatric and adult
age groups with acne
vulgaris.
A thorough literature
search was
conducted based on
the methods used in
the European
Dermatology Forum
guideline. This
original search was
updated from March
2010 to July 2015.
Inclusion criteria for
this guideline
consisted of
human/clinical
studies, systematic
reviews, metaanalyses, RCTs, and
controlled
prospective studies.

Comedonal Acne – topical
retinoids*, benzoyl peroxide
(BP), combination clindamycin
+ BP, and combination
adapalene + BP have a
medium strength
recommendation.

Level I

Adapted and
expanded
upon from
the
European
Dermatology
Forum
guideline.

Evaluation to
determine type,
extent, and distribution
of acne should be
completed using a
scale of clear, almost
clear, mild, moderate,
and severe/extreme.
This scale determines
change over time. The
overall goal is a
change of two grades
or achieving clear or
almost clear after
treatment.

Mild-to-Moderate
Papulopustular Acne –
combination adapalene + BP
and combination clindamycin +
BP have a high strength
recommendation. BP, topical
retinoids*, systemic
antibiotics** combined with BP
+/- topical retinoids*, and
combined oral contraceptives
have a medium strength
recommendation.

Assessing patient’s
quality of life through
direct inquiry or with
the use of the AcneQ4 or Cardiff Acne
Disability Index (CADI) Severe Acne – oral isotretinoin
instruments can be
monotherapy has a high
helpful.
strength recommendation.
Systemic antibiotics**
combined with BP +/- a topical
retinoid* has a medium
strength recommendation.

High
Quality
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*adapalene or tazarotene
preferred

Friedman, A., Waite,
K., Brandt, S., &
Meckfessel, M. H.
(2016). Accelerated
onset of action and
increased tolerability
in treating acne with
a fixed-dose
combination gel.
Journal of Drugs in
Dermatology, 15(2),
231-236.

Discuss the
effectiveness of
combination
adapalene
0.1%/benzoyl
peroxide 2.5% (ABP) gel on the
treatment of acne.

MetaAnalysis

Reviewed data from
14 clinical studies
with a total of 2,358
subjects that were
treated with A-BP.

Lesion counts were
assessed at baseline
and at each visit. The
post-baseline lesion
count was subtracted
from the baseline
lesion count to
determine
improvement.
Investigator global
assessment (IGA)
scores were assessed
using a scale of 0
(clear) to 4 (very
severe).
Tolerability of
medications was
assessed using 4point scales (ranging
from none to severe)
to evaluate dryness,
erythema, scaling, and
stinging/burning.

Gollnick, H. P. M.,
Friedrich, M.,

Determine
effectiveness and

Descriptive
Study

The study took place
within 178 centers in

Safety and tolerability
were assessed using

**tetracycline or doxycycline
preferred
“Median total lesion counts
decreased 40.8% from
baseline to week 4” (p. 232).

Level I
Good
Quality

“Subjects with IGA scores of
moderate to severe at baseline
had a slightly better
improvement compared to
subjects with an IGA score of
mild…however, subjects with
an IGA score of mild at
baseline had better
improvement in
noninflammatory lesion
reductions compared to
subjects with baseline IGA
scores of moderate to severe”
(p. 232).
Inflammatory and
noninflammatory lesions
decreased 46.2% and 37.5%,
respectively, from baseline to
week 4.
Tolerability was ranked as
none or mild with the majority
of subjects (see Figure 4).
Acne severity decreased from
5.6 ± 1.5 at baseline to 3.3 ±

Level
VI
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Peschen, M.,
Pettker, R., Pier, A.,
Streit, V.,
Jostingmeyer, P.,
Porombka, D., Rojo
Pulido, I., & Jackel,
A. (2015). Safety
and efficacy of
adapalene
0.1%/benzoyl
peroxide 2.5% in the
long-term treatment
of predominantly
moderate acne with
or without
concomitant
medication – results
from the noninterventional cohort
study ELANG.
Journal of the
European Academy
of Dermatology and
Venereology,
29(S4), 15-22.

safety of
combination
adapalene
0.1%/benzoyl
peroxide 2.5%
(adapalene-BP)
for the long-term
management of
moderate to
severe acne.
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Germany.
Observations were
made among 5,131
patients with
moderate to severe
acne (grades 4-12 on
the Leeds Revised
Acne Grading Scale).
Observations took
place over a period of
nine months.
Patients were
selected based on
whether “acne
therapy with
adapalene-BP alone
or in combination
with other drugs was
indicated” (p. 17).

a 4-step scale (none,
mild, moderate,
severe) to evaluate
local skin irritation
including issues such
as erythema, dryness,
desquamation,
burning/stinging, and
pruritis at each follow
up visit. Overall
tolerability with
treatment was also
assessed using a 4step scale (very good,
good, satisfactory,
poor) at baseline and
during the final visit.
Adverse drug
reactions were
assessed during each
visit as well.
Efficacy was
measured using the
Leeds Revised Acne
Grading System and
physician assessment
(very good, good,
satisfactory, poor) to
note changes in the
severity of acne at
each visit. Patient
assessment of
efficacy was
measured at 3 months
as well as “time to

1.9 at 3 months and 1.9 ± 1.9
at 9 months based on the
Leeds Revised Acne Grading
System. After treatment, 420
patients (8.2%) experienced
completely clear (no visible
lesions) at 3 months and 1326
patients (25.8%) at 9 months.
Treatment was similar
between patients who received
adapalene-BP alone and those
who were receiving
adapalene-BP in combination
with a systemic antibiotic.
Physician assessment of
treatment efficacy was rated
as good or very good for
83.1% of the patients.
Tolerability was rated as good
or very good for 90.2% of
patients.
49.5 of patients experienced
skin irritation (dryness 30.7%;
erythema 24.3%; and
desquamation 22.4%).

High
Quality
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Gollnick, H. P. M.,
Funke, G., Kors, C.,
Titzmann, T.,
Jostingmeyer, P., &
Jackel, A. (2015).
Efficacy of
adapalene/benzoyl
peroxide
combination in
moderate
inflammatory acne
and its impact on
patient adherence.
Journal of the
German Society of
Dermatology, 13(6),
557-565.

Determine efficacy
and patient
adherence with
adapalene
0.1%/benzoyl
peroxide 2.5%
(adapalene-BP) in
patients with
moderate
inflammatory
acne.

Descriptive
Study

73

A total of 2,780
patients with
moderate
inflammatory acne
were observed for 12
weeks within 314
dermatology centers
throughout Germany.
Patients were
between the ages of
12 and 20 years old.

onset of action
observed by the
patient” (p. 17) using a
6-item scale
(completely resolved,
marked improvement,
moderate
improvement, mild
improvement, no
change, worsened)
Skin irritation was
assessed using a
scale (none, mild,
moderate, severe) to
rate degree of
erythema, dryness,
desquamation,
burning/stinging, and
pruritis at each follow
up visit. Adverse drug
reactions were also
noted at each follow
up visit.
Physicians rated
tolerability using a 4item scale (very good,
good, satisfactory,
poor).
The Leeds grading
system was used to
assess changes in the
severity of acne.

Acne severity decreased from
4.8 ± 0.9 at baseline to 2.1 ±
1.6 at 12 weeks based on the
Leeds scale. Efficacy was
rated by physicians as good or
very good in 79.2% of patients.
Skin irritation was rated as
none (19%), mild (51%),
moderate (24%), and severe
(6%).
Tolerability was rated as good
or very good by physicians for
82.8% of patients.
Overall, 63.2% of patients
were considered adherent to
treatment.
82.3% of patients were either
satisfied or very satisfied with
treatment and physicians rated
treatment as good or very
good for 80.1% of patients.

Level
VI
High
Quality
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Efficacy of treatment
was assessed by the
physicians using a 4item scale (very good,
good, satisfactory,
poor). Patients also
assessed efficacy
using a 6-item scale
(completely cured,
marked improvement,
moderate
improvement, slight
improvement, no
change, worsened).

Le Cleach, L.,
Lebrun-Vignes, B.,
Bachelot, A., Beer,
F., Berger, P.,
Brugere, S.,
Chastaing, M., DoPham, G., Ferry, T.,
Gand-Gavanou, J.,
Guigues, B., JoinLambert, O., Henry,
P., Khallouf, R.,
Lavie, E., Maruani,
A., Romain, O.,
Sassolas, B., Tran,
V. T., & Guillot, B.
(2017). Guidelines
for the management

Provide
Clinical
recommendations Practice
on the treatment of Guideline
acne vulgaris.

A literature search
was conducted to
find relevant
references between
2007 and September
2014. This search
was then updated to
include references up
to July 2016. A total
of 128 references
were included in this
guideline. Selection
criteria included
systematic reviews,
RCTs, and
observational
studies.

Treatment adherence
was assessed using a
4-item questionnaire
at the final visit.
The Global Acne
Severity scale was
used as the basis for
recommendations and
the development of
the treatment
algorithm.

Almost clear skin – benzoyl
peroxide or a topical retinoid is
recommended for first line
treatment.
Mild – benzoyl peroxide and a
topical retinoid is
recommended for first line
treatment.
Moderate – benzoyl peroxide
and a topical retinoid OR the
previously mentioned
treatment with the addition of
oral doxycycline or lymecycline
is recommended for first line
treatment.

Level I
High
Quality
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of acne:
Recommendations
from a French
multidisciplinary
group. British
Journal of
Dermatology, 177,
908-913.

Severe – oral doxycycline or
lymecycline, benzoyl peroxide,
and a topical retinoid are
recommended for first line
treatment. Oral isotretinoin can
be considered for first line
treatment if risk of scarring is
high.
Very severe – Oral isotretinoin
is recommended for first line
treatment.

Nast, A., Dreno, B.,
Bettoli, V., Bukvic
Mokos, Z., Degitz,
K., Dressler, C.,
Finlay, A. Y.,
Haedersdal, M.,
Lambert, J., Layton,
A., Lomholt, H. B.,
Lopez-Estebaranz,
J. L., Ochsendorf,
F., Oprica, C.,
Rosumeck, S.,
Simonart, T.,
Werner, R. N., &
Gollnick, H. (2016).
European evidence-

Provide
recommendations
for the treatment
of acne vulgaris.

Clinical
Practice
Guideline

A thorough literature
search was
conducted from 2010
to July 2015.
Inclusion criteria
involved RCTs that
evaluated acne
treatments. Overall,
data from 154 studies
were utilized to form
this guideline.

No recommended
global system for
measuring acne
severity has been
identified.
Subjective grading of
acne severity, in
addition to lesion
counts, is considered
practical for clinical
practice.
Classification of acne
for this guideline
consisted of 1)

Oral doxycycline and
lymecycline should be limited
to 3 months. These
medications should also be
combined with topical
therapies.
Comedonal Acne – topical
retinoids* have a medium
strength recommendation.
Mild to Moderate
Papulopustular Acne –
Adapalene + BP or BP +
clindamycin has a high
strength of recommendation.
Azelaic acid, BP, topical
retinoid*, topical clindamycin +
tretinoin, or systemic
antibiotic** + adapalene have
a medium strength
recommendation.

Level I
High
Quality
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based (S3) guideline
for the treatment of
acne. European
Dermatology Forum.

comedonal acne, 2)
mild-moderate
papulopustular acne,
3) severe
papulopustular
acne/moderate
nodular acne, and 4)
severe nodular
acne/conglobate acne.
Quality of life
measures is
recommended for
acne management.
No one questionnaire
is recommended over
the others.

Yang, Z., Zhang, Y.,
Mosler, E. L., Hu, J.,
Li, H., Zhang, Y.,
Liu, J., & Zhang, Q.
(2020). Topical
benzoyl peroxide for
acne. Cochrane
Database of
Systematic Reviews.

Evaluate the
effectiveness of
using BP for the
treatment of acne

Systematic
Review

A thorough literature
search was
conducted in multiple
databases until
February 2019.
A total of 120 RCTs
with 29,592 subjects
were included within
this review.

The primary outcomes
measured were
participant selfassessment of acne
improvement using a
Likert scale and
withdrawal due to
adverse events.
Secondary outcomes
included investigatorassessed changes in

Severe
Papulopustular/Moderate
Nodular Acne – isotretinoin
has a high strength
recommendation. Systemic
antibiotic** + adapalene,
systemic antibiotic** + azelaic
acid, or systemic antibiotic** +
adapalene + BP have a
medium strength
recommendation.
Severe Nodular/Conglobate
Acne – isotretinoin has a high
strength recommendation.
Systemic antibiotic** + azelaic
acid or systemic antibiotic** +
adapalene + BP have a
medium strength
recommendation.
*Adapalene is preferred
** Doxycycline or lymecycline
are preferred
BP compared to placebo/no
treatment – participant selfassessment of improvement
was slightly better compared
to placebo/no treatment (RR =
1.27). However, participants
were twice as likely to
withdraw from BP treatment
due to adverse effects (RR =
2.13).

Level I
High
Quality
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Subjects within the
studies had either
mild, moderate, or
severe acne.

lesion counts,
percentage of
participants
considered clear or
almost clear on the
IGA scale, changes in
quality of life,
reduction of C acnes
strains, and
percentage of
participants
experiencing adverse
events.
Comparisons were
made between BP
and 47 other acne
treatments. The main
comparisons were
placebo/no treatment,
adapalene,
clindamycin,
erythromycin, and
salicylic acid.

Zaenglein, A. L.,
Pathy, A. L.,
Schlosser, B. J.,
Alikhan, A., Baldwin,
H. E., Berson, D. S.,

Provide updated
recommendations
on the
management acne
vulgaris in

Clinical
Practice
Guideline

A thorough literature
search was
conducted between
May 2006 and
September 2014 to

No universal acne
grading system is
recommended.

BP compared to adapalene –
There was no difference of
participant self-assessment of
improvement between
treatment with BP and
adapalene (RR = 0.99).
However, participants were
more likely to withdraw from
BP treatment due to adverse
effects (RR = 1.85).
BP compared to clindamycin –
Participant self-assessment
was slightly better with the
clindamycin group compared
to BP (RR = 0.95). BP group
was almost twice as likely to
withdraw due to adverse
effects (RR = 1.93).
BP compared to erythromycin
– No data was available for
participant self-assessment.
There was no difference
between withdrawal rate
between the two groups (RR =
1.0).
BP compared to salicylic acid No data was available for
primary outcomes.
Mild Acne – BP, topical
retinoid, or topical combination
therapy* are recommended as
first line treatment.

Level I
Good
Quality
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Bowe, W. P.,
Graber, E. M.,
Harper, J. C., Kang,
S., Keri, J. E.,
Leyden, J. J.,
Reynolds, R. V.,
Silverberg, N. B.,
Gold, L. F. S.,
Tollefson, M. M.,
Weiss, J. S., Dolan,
N. C., Sagan, A. A.,
. . . Bhushan, R.
(2016). Guidelines
of care for the
management of
acne vulgaris.
Journal of the
American Academy
of Dermatology,
74(5), 945-973.e33.

adolescent and
adult patients.

78
update the previous
guideline from 2007.

The use of a
consistent grading
system among
clinicians is
recommended to
determine acne
severity and response
to treatment.

Moderate Acne –topical
combination therapy*, oral
antibiotic*** + topical retinoid +
BP, or oral antibiotic*** +
topical retinoid + BP + topical
antibiotic** is recommended
for first line treatment.
Severe Acne – oral
antibiotic*** + topical
combination therapy* or oral
isotretinoin is recommended
as first line treatment.
*BP + topical antibiotic** OR
retinoid + BP OR retinoid + BP
+ topical antibiotic**
**clindamycin 1% is the
preferred topical antibiotic
***doxycycline or minocycline
are the preferred oral
antibiotics
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Appendix D
Acne Treatment Algorithm
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Appendix E
Modified IGA Scale

Grade
0

Description
Clear skin with no inflammatory or noninflammatory lesions

1

Almost clear; rare noninflammatory lesions with no more than one
small inflammatory lesion

2

Mild severity; greater than Grade 1; some inflammatory lesions with
no more than a few inflammatory lesions (papules/pustules only, no
nodular lesions)

3

Moderate severity; greater than Grade 2; up to many
noninflammatory lesions and may have some inflammatory lesions,
but no more than one small nodular lesion

4

Severe; greater than Grade 3; up to many noninflammatory lesions
and may have some inflammatory lesions, but no more than a few
nodular lesions

5

Very severe; greater than Grade 4; many noninflammatory and
inflammatory lesions and more than a few nodular lesions; cystic
lesions may be present

Note:

Noninflammatory lesions: open (blackheads) or closed (whiteheads)
comedones
Inflammatory lesions: papules, pustules, and nodules

Modified from U.S. Department of Health and Human Services Food and Drug Administration
Center for Drug Evaluation and Research (CDER) Investigator Global Assessment (IGA) Scale
Food and Drug Administration. (2005). Guidance for industry acne vulgaris: Developing drugs
for treatment (Docket ID. FDA-2005-D-0461-0002). U.S. Department of Health and Human
Services. https://www.regulations.gov/document?D=FDA-2005-D-0461-0002
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Appendix F
Acne Treatment Policy

Owner:
Function: Patient Care
Department(s): Health Center
Scope: Physician, Nurse Practitioner

Policy & Procedure
Policy Origin Date: 2020
Effective Date: Sept. 2020
Reviewed/Recommended By: Health Center
Director
Approved By:
Approval Date:

Treatment Algorithm for the Management of Acne Vulgaris
Departments Affected: Health Center
Scope of Practice: Nurse Practitioner
Policy Statement:
This policy/procedure provides instructions for using a treatment algorithm to manage patients
presenting to the health center with acne vulgaris.
Procedure:
1. Using the modified Investigator Global Assessment (IGA) scale, rate the patient’s acne
severity as either 0) clear, 1) almost clear, 2) mild, 3) moderate, 4) severe, or 5) very
severe. See notes for IGA scale.
2. Based on the modified IGA severity rating, use the treatment algorithm to determine the
appropriate medications to manage the patient’s acne.
a. For acne rated as 1) almost clear, it is recommended to use either topical benzoyl
peroxide 2.5% or topical adapalene 0.1%
b. For acne rated as 2) mild or 3) moderate, it is recommended to use both topical
benzoyl peroxide 2.5% and topical adapalene 0.1% as first line agents. There are
also strong recommendations for the use of both topical benzoyl peroxide 2.5%
and topical clindamycin 1%, however, these should be used as second line agents
based on the greater amount of evidence that favors the first line agents.
c. For acne rated as 4) severe or 5) very severe, it is recommended to use a
combination of topical benzoyl peroxide 2.5%, topical adapalene 0.1%, and
systemic doxycycline.
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3. Medications should be dosed and administered* as follows or based on clinical
judgement:
a.
b.
c.
d.

Topical benzoyl peroxide 2.5% once in the morning after washing face
Topical adapalene 0.1% once in the evening after washing face
Topical clindamycin 1% twice daily
Systemic doxycycline 100 mg twice daily

Notes:
*Benzoyl peroxide 2.5%, clindamycin phosphate 1%, and doxycycline will be kept on hand at
the student health center. A prescription for adapalene 0.1% will be required for the student.
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Appendix G
Informed Consent Form

Code #______
Title of EBP Project
Implementation of a Cost-Effective Treatment Algorithm for the Management of Acne Vulgaris
in College Students
Principal Investigator
Cristina Borsilli, BSN, RN, DNP Student Valparaiso University
(219) 671-7344
cristina.borsilli@valpo.edu
Faculty Supervisor
Alesha McClanahan, DNP, RN, FNP-BC
(219) 689-3369
alesha.mcclanahan@valpo.edu
Purpose of EBP Project
You are being asked to take part in an evidence-based practice (EBP) project. Before you decide
to participate, it is important that you understand why this EBP project is being done and what it
will involve. Please read the following information carefully. Please ask the principal
investigator if there is anything that is not clear or if you need more information.
The purpose of this EBP project is to determine the effects of using a treatment algorithm for the
management of acne. Treatments included within the algorithm have been selected based on the
best available evidence and affordability.
Project Procedures
During appointments at the student health center, the principal investigator will determine if you
are being seen for acne, are 18 years and older, and are not currently pregnant or breastfeeding. If
these factors are met, the health care provider (either a doctor or nurse practitioner) will assess
the severity of your acne and then follow the treatment algorithm developed for this project to
treat your acne. The treatment algorithm determines which type of medication should be used for
different levels of acne based on severity. Acne can be classified as clear, almost clear, mild,
moderate, severe, or very severe. The medications included in the treatment algorithm include
benzoyl peroxide, adapalene, clindamycin, and doxycycline. These medications have all been
previously used and approved for practice and are not experimental in any way. During your first
visit, you will also be asked to fill out a questionnaire about your acne. After your first visit at
the health center, you will be asked to fill out the questionnaire again after 6 weeks to see if there
has been any improvement with the treatment you were prescribed. This EBP project will last
approximately 6 weeks.
Risks
Potential risks for participating in this EBP project are minimal and involve embarrassment
related to acne and potential side effects from the medications used to manage acne. These side
effects can include redness, dryness, itching, burning/stinging, or peeling of the skin; rashes;
nausea; vomiting; or diarrhea. In rare cases allergic reactions, sun sensitivity, face or eyelid
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swelling, lip or tongue swelling, or liver issues may occur. Let the principal investigator or
healthcare provider know if you experience any of these. There may also be drug interactions
that can occur with these medications. You should let the health care provider know about all of
the medications you are currently taking, including over-the-counter medications as well as
vitamins, supplements, or herbal remedies.
Benefits
There are multiple benefits of participating in this EBP project. You will be receiving treatment
based on recommendations from the best available evidence. The goals of using these treatment
options are to improve your acne while being affordable. The primary investigator hopes to gain
valuable information about the use of a treatment algorithm and acne severity scales for treating
acne. The results from this EBP project may help to advance nursing practice and knowledge as
well.
Confidentiality
All efforts will be made by the primary investigator to keep your personal information
confidential. All records containing your personal information will be kept in a locked box with
access permitted only to the primary investigator. To further increase confidentiality, a code will
be assigned to you for questionnaire forms. Any information stored on a computer will be
password protected and accessed only by the primary investigator.
Contact Information
If you have questions at any time about this EBP project, or you experience adverse effects as the
result of participating in this EBP project, you may contact the primary investigator whose
contact information is provided on the first page. If you have questions regarding your rights as a
project participant, or if problems arise which you do not feel you can discuss with the primary
investigator, please contact the Valparaiso University Institutional Review Board at
valpoirb@valpo.edu or 219-464-5798.
Voluntary Participation
Your participation in this EBP project is voluntary. It is up to you to decide whether or not to
take part in this project. If you decide to take part in this EBP project, you will be asked to sign a
consent form. After you sign the consent form, you are still free to withdraw at any time and
without giving a reason. Withdrawing from this EBP project will not affect the relationship you
have, if any, with the principal investigator or health care providers. If you withdraw from the
EBP project before data collection is completed, your data will be destroyed.
You may decline to answer any or all questions and you may terminate your involvement at any
time if you choose.
I have read and I understand the provided information and have had the opportunity to ask
questions. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason and without cost. I understand that I will be given a copy of this
consent form. I voluntarily agree to take part in this EBP project.
Participant’s Signature
Investigator’s Signature

Date ____________
Date ____________

ACNE VULGARIS TREATMENT ALGORITHM

87

Appendix H
Demographic Form

Implementation of a Cost-Effective Treatment Algorithm for the
Management of Acne Vulgaris in College Students
Principal Investigator: Cristina Borsilli, BSN, RN, DNP Student Valparaiso University

Demographic Form
Instructions: Please answer the questions provided below by printing your responses and
checking the appropriate boxes. Return this form to the principal investigator when you are
finished. The purpose of this form is to collect relevant demographic data of each participant
involved in the EBP project. All responses contained in this document will be kept confidential.

1. Date: ____/____/____
2. Name: ____________________________
3. Phone Number: ____________________
4. Email: ____________________________
5. Age: ____________

6. Gender: □ Female

□ Male

7. Ethnicity/Race:
□ African American
□ Asian
□ Caucasian
□ Hispanic
□ Native American
□ Other: ____________________
□ Unknown
□ Prefer not to answer
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8. Marital Status: □ Single

□ Married
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□ Divorced/Separated

9. Highest Level of Education Completed:
□ Less than high school
□ High school/GED
□ Some college (no degree)
□ Associate’s degree (2-year degree)
□ Bachelor’s degree (4-year degree)
□ Master’s degree
□ Doctoral degree
10. Employment Status:
□ Full time (40 or more hours per week)
□ Part time (up to 39 hours per week)
□ Unemployed and currently seeking work
□ Unemployed and not currently seeking work
□ Student
□ Homemaker
□ Retired
□ Self-employed
□ Unable to work
11. Annual Household Income:
□ Less than $19,999
□ $20,000 to $34,999
□ $35,000 to $49,999
□ $50,000 to $74,999
□ $75,000 to $99,999
□ Over $100,000

□ Widowed
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Appendix I
CITI Completion Certificate

